{
  "label": "distractor_outline_vaccine_immunogenicity",
  "artifact_type": "distractor_outline",
  "artifact_id": "sha256:b9a5f4498416bfb2148e106e9d25ca838481bb56025a18e16baf31718f4ee4a2",
  "input_ids": [
    "sha256:b4ba5337b06c8de68ac3315db1a4f6980c5bd48efd529c3914f30297d6afd329"
  ],
  "prompt_id": null,
  "model_config": null,
  "created_at": "2026-02-17T11:53:46.685283",
  "content": "{\n  \"episodes\": [\n    {\n      \"index\": 1,\n      \"date\": \"2024-03-04\",\n      \"theme\": \"vaccine_immunogenicity\",\n      \"enrollment\": {\n        \"total_enrolled\": 45,\n        \"active\": 45,\n        \"screen_failures_cumulative\": 1,\n        \"withdrawals_cumulative\": 0,\n        \"by_dose_group\": {\n          \"low_dose\": 12,\n          \"mid_dose\": 10,\n          \"high_dose\": 12,\n          \"placebo\": 11\n        }\n      },\n      \"immunogenicity_by_group\": {\n        \"low_dose\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 20.2,\n            \"sd\": 6.0\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 14.0,\n            \"sd\": 4.0\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 40.3,\n            \"sd\": 10.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 64.0,\n            \"sd\": 15.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 38.0,\n            \"sd\": 11.0\n          },\n          \"seroconversion_pct\": 9.0\n        },\n        \"mid_dose\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 38.6,\n            \"sd\": 9.6\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 20.5,\n            \"sd\": 6.4\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 70.7,\n            \"sd\": 16.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 104.0,\n            \"sd\": 24.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 73.0,\n            \"sd\": 18.0\n          },\n          \"seroconversion_pct\": 16.0\n        },\n        \"high_dose\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 51.7,\n            \"sd\": 13.2\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 30.0,\n            \"sd\": 8.8\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 91.9,\n            \"sd\": 22.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 134.0,\n            \"sd\": 33.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 89.0,\n            \"sd\": 24.0\n          },\n          \"seroconversion_pct\": 26.9\n        },\n        \"placebo\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 1.8,\n            \"sd\": 1.2\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 3.8,\n            \"sd\": 0.8\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 4.0,\n            \"sd\": 2.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 5.0,\n            \"sd\": 3.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 3.0,\n            \"sd\": 2.0\n          },\n          \"seroconversion_pct\": 1.9\n        }\n      },\n      \"injection_site_reactions\": {\n        \"pain_pct\": 62.5,\n        \"erythema_pct\": 23.4,\n        \"swelling_pct\": 8.3,\n        \"induration_pct\": 9.7,\n        \"mean_pain_duration_hours\": 46.1\n      },\n      \"systemic_reactogenicity\": {\n        \"fever_pct\": 16.8,\n        \"fatigue_pct\": 20.1,\n        \"myalgia_pct\": 20.3,\n        \"headache_pct\": 16.0,\n        \"chills_pct\": 6.3\n      },\n      \"safety_labs\": {\n        \"wbc_k\": {\n          \"mean\": 7.5,\n          \"sd\": 1.2\n        },\n        \"lymphocyte_pct\": {\n          \"mean\": 30.5,\n          \"sd\": 7.3\n        },\n        \"neutrophil_pct\": {\n          \"mean\": 53.9,\n          \"sd\": 9.7\n        },\n        \"platelets_k\": {\n          \"mean\": 222,\n          \"sd\": 43\n        },\n        \"crp_mg_l\": {\n          \"mean\": 6.4,\n          \"sd\": 1.5\n        },\n        \"hemoglobin_g_dl\": {\n          \"mean\": 14.1,\n          \"sd\": 0.9\n        }\n      },\n      \"adverse_events\": [\n        {\n          \"ae_id\": \"VI-AE-0187\",\n          \"description\": \"arthralgia\",\n          \"grade\": 2,\n          \"relatedness\": \"possibly related\",\n          \"resolved\": true,\n          \"dose_group\": \"mid_dose\"\n        },\n        {\n          \"ae_id\": \"VI-AE-0156\",\n          \"description\": \"malaise\",\n          \"grade\": 1,\n          \"relatedness\": \"possibly related\",\n          \"resolved\": true,\n          \"dose_group\": \"high_dose\"\n        }\n      ],\n      \"events\": [\n        \"Site 05 monitoring visit, 2 minor findings\",\n        \"Cold chain temperature log reviewed: all within -70C +/- 5C\",\n        \"Serum sample aliquoting completed for 14 subjects\"\n      ],\n      \"notes\": \"Week 1: Immunogenicity assessments on schedule. 45 subjects enrolled across dose groups. Reactogenicity profiles consistent with prior weeks.\"\n    },\n    {\n      \"index\": 2,\n      \"date\": \"2024-03-11\",\n      \"theme\": \"vaccine_immunogenicity\",\n      \"enrollment\": {\n        \"total_enrolled\": 55,\n        \"active\": 55,\n        \"screen_failures_cumulative\": 3,\n        \"withdrawals_cumulative\": 0,\n        \"by_dose_group\": {\n          \"low_dose\": 14,\n          \"mid_dose\": 14,\n          \"high_dose\": 13,\n          \"placebo\": 14\n        }\n      },\n      \"immunogenicity_by_group\": {\n        \"low_dose\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 24.1,\n            \"sd\": 6.0\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 14.3,\n            \"sd\": 4.0\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 32.3,\n            \"sd\": 10.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 65.0,\n            \"sd\": 15.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 42.0,\n            \"sd\": 11.0\n          },\n          \"seroconversion_pct\": 5.8\n        },\n        \"mid_dose\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 40.1,\n            \"sd\": 9.6\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 17.6,\n            \"sd\": 6.4\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 67.5,\n            \"sd\": 16.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 94.0,\n            \"sd\": 24.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 74.0,\n            \"sd\": 18.0\n          },\n          \"seroconversion_pct\": 11.3\n        },\n        \"high_dose\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 50.5,\n            \"sd\": 13.2\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 24.9,\n            \"sd\": 8.8\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 82.0,\n            \"sd\": 22.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 125.0,\n            \"sd\": 33.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 95.0,\n            \"sd\": 24.0\n          },\n          \"seroconversion_pct\": 19.9\n        },\n        \"placebo\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 6.7,\n            \"sd\": 1.2\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 0.2,\n            \"sd\": 0.8\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 1.3,\n            \"sd\": 2.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 5.0,\n            \"sd\": 3.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 2.0,\n            \"sd\": 2.0\n          },\n          \"seroconversion_pct\": 0\n        }\n      },\n      \"injection_site_reactions\": {\n        \"pain_pct\": 44.4,\n        \"erythema_pct\": 12.8,\n        \"swelling_pct\": 6.8,\n        \"induration_pct\": 10.9,\n        \"mean_pain_duration_hours\": 12.5\n      },\n      \"systemic_reactogenicity\": {\n        \"fever_pct\": 13.9,\n        \"fatigue_pct\": 43.5,\n        \"myalgia_pct\": 24.5,\n        \"headache_pct\": 29.3,\n        \"chills_pct\": 7.2\n      },\n      \"safety_labs\": {\n        \"wbc_k\": {\n          \"mean\": 7.6,\n          \"sd\": 2.0\n        },\n        \"lymphocyte_pct\": {\n          \"mean\": 37.7,\n          \"sd\": 5.2\n        },\n        \"neutrophil_pct\": {\n          \"mean\": 61.7,\n          \"sd\": 9.6\n        },\n        \"platelets_k\": {\n          \"mean\": 250,\n          \"sd\": 42\n        },\n        \"crp_mg_l\": {\n          \"mean\": 5.0,\n          \"sd\": 1.2\n        },\n        \"hemoglobin_g_dl\": {\n          \"mean\": 13.1,\n          \"sd\": 0.8\n        }\n      },\n      \"adverse_events\": [\n        {\n          \"ae_id\": \"VI-AE-0287\",\n          \"description\": \"lymphadenopathy\",\n          \"grade\": 2,\n          \"relatedness\": \"possibly related\",\n          \"resolved\": true,\n          \"dose_group\": \"high_dose\"\n        },\n        {\n          \"ae_id\": \"VI-AE-0212\",\n          \"description\": \"chills\",\n          \"grade\": 2,\n          \"relatedness\": \"possibly related\",\n          \"resolved\": true,\n          \"dose_group\": \"high_dose\"\n        },\n        {\n          \"ae_id\": \"VI-AE-0254\",\n          \"description\": \"injection site pain\",\n          \"grade\": 2,\n          \"relatedness\": \"possibly related\",\n          \"resolved\": true,\n          \"dose_group\": \"low_dose\"\n        },\n        {\n          \"ae_id\": \"VI-AE-0286\",\n          \"description\": \"lymphadenopathy\",\n          \"grade\": 1,\n          \"relatedness\": \"possibly related\",\n          \"resolved\": true,\n          \"dose_group\": \"mid_dose\"\n        }\n      ],\n      \"events\": [\n        \"Site 03 monitoring visit, 1 minor findings\",\n        \"T-cell assay batch B02 processed, results QC'd\"\n      ],\n      \"notes\": \"Week 2: Immunogenicity assessments on schedule. 55 subjects enrolled across dose groups. Reactogenicity profiles consistent with prior weeks.\"\n    },\n    {\n      \"index\": 3,\n      \"date\": \"2024-03-18\",\n      \"theme\": \"vaccine_immunogenicity\",\n      \"enrollment\": {\n        \"total_enrolled\": 67,\n        \"active\": 67,\n        \"screen_failures_cumulative\": 5,\n        \"withdrawals_cumulative\": 0,\n        \"by_dose_group\": {\n          \"low_dose\": 18,\n          \"mid_dose\": 17,\n          \"high_dose\": 16,\n          \"placebo\": 16\n        }\n      },\n      \"immunogenicity_by_group\": {\n        \"low_dose\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 24.8,\n            \"sd\": 6.0\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 14.9,\n            \"sd\": 4.0\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 38.8,\n            \"sd\": 10.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 65.0,\n            \"sd\": 15.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 45.0,\n            \"sd\": 11.0\n          },\n          \"seroconversion_pct\": 11.9\n        },\n        \"mid_dose\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 48.1,\n            \"sd\": 9.6\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 24.3,\n            \"sd\": 6.4\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 72.3,\n            \"sd\": 16.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 106.0,\n            \"sd\": 24.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 77.0,\n            \"sd\": 18.0\n          },\n          \"seroconversion_pct\": 14.5\n        },\n        \"high_dose\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 63.5,\n            \"sd\": 13.2\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 30.5,\n            \"sd\": 8.8\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 95.5,\n            \"sd\": 22.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 152.0,\n            \"sd\": 33.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 108.0,\n            \"sd\": 24.0\n          },\n          \"seroconversion_pct\": 29.4\n        },\n        \"placebo\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 10.7,\n            \"sd\": 1.2\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 2.9,\n            \"sd\": 0.8\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 4.6,\n            \"sd\": 2.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 5.0,\n            \"sd\": 3.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 7.0,\n            \"sd\": 2.0\n          },\n          \"seroconversion_pct\": 6.9\n        }\n      },\n      \"injection_site_reactions\": {\n        \"pain_pct\": 51.7,\n        \"erythema_pct\": 14.6,\n        \"swelling_pct\": 7.8,\n        \"induration_pct\": 10.0,\n        \"mean_pain_duration_hours\": 25.5\n      },\n      \"systemic_reactogenicity\": {\n        \"fever_pct\": 18.2,\n        \"fatigue_pct\": 32.7,\n        \"myalgia_pct\": 25.9,\n        \"headache_pct\": 17.3,\n        \"chills_pct\": 14.8\n      },\n      \"safety_labs\": {\n        \"wbc_k\": {\n          \"mean\": 8.9,\n          \"sd\": 1.9\n        },\n        \"lymphocyte_pct\": {\n          \"mean\": 28.7,\n          \"sd\": 6.8\n        },\n        \"neutrophil_pct\": {\n          \"mean\": 62.2,\n          \"sd\": 6.2\n        },\n        \"platelets_k\": {\n          \"mean\": 216,\n          \"sd\": 39\n        },\n        \"crp_mg_l\": {\n          \"mean\": 6.3,\n          \"sd\": 1.9\n        },\n        \"hemoglobin_g_dl\": {\n          \"mean\": 13.8,\n          \"sd\": 1.3\n        }\n      },\n      \"adverse_events\": [\n        {\n          \"ae_id\": \"VI-AE-0303\",\n          \"description\": \"lymphadenopathy\",\n          \"grade\": 1,\n          \"relatedness\": \"possibly related\",\n          \"resolved\": true,\n          \"dose_group\": \"high_dose\"\n        },\n        {\n          \"ae_id\": \"VI-AE-0346\",\n          \"description\": \"fever\",\n          \"grade\": 1,\n          \"relatedness\": \"possibly related\",\n          \"resolved\": true,\n          \"dose_group\": \"mid_dose\"\n        },\n        {\n          \"ae_id\": \"VI-AE-0386\",\n          \"description\": \"injection site pain\",\n          \"grade\": 2,\n          \"relatedness\": \"related\",\n          \"resolved\": true,\n          \"dose_group\": \"low_dose\"\n        }\n      ],\n      \"events\": [\n        \"Serum sample aliquoting completed for 25 subjects\",\n        \"Serum sample aliquoting completed for 19 subjects\"\n      ],\n      \"notes\": \"Week 3: Immunogenicity assessments on schedule. 67 subjects enrolled across dose groups. Reactogenicity profiles consistent with prior weeks.\"\n    },\n    {\n      \"index\": 4,\n      \"date\": \"2024-03-25\",\n      \"theme\": \"vaccine_immunogenicity\",\n      \"enrollment\": {\n        \"total_enrolled\": 80,\n        \"active\": 80,\n        \"screen_failures_cumulative\": 6,\n        \"withdrawals_cumulative\": 0,\n        \"by_dose_group\": {\n          \"low_dose\": 20,\n          \"mid_dose\": 21,\n          \"high_dose\": 20,\n          \"placebo\": 19\n        }\n      },\n      \"immunogenicity_by_group\": {\n        \"low_dose\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 32.6,\n            \"sd\": 6.0\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 16.9,\n            \"sd\": 4.0\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 46.4,\n            \"sd\": 10.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 85.0,\n            \"sd\": 15.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 54.0,\n            \"sd\": 11.0\n          },\n          \"seroconversion_pct\": 12.1\n        },\n        \"mid_dose\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 52.1,\n            \"sd\": 9.6\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 25.3,\n            \"sd\": 6.4\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 80.7,\n            \"sd\": 16.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 120.0,\n            \"sd\": 24.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 90.0,\n            \"sd\": 18.0\n          },\n          \"seroconversion_pct\": 19.6\n        },\n        \"high_dose\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 71.3,\n            \"sd\": 13.2\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 33.2,\n            \"sd\": 8.8\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 122.2,\n            \"sd\": 22.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 178.0,\n            \"sd\": 33.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 121.0,\n            \"sd\": 24.0\n          },\n          \"seroconversion_pct\": 25.2\n        },\n        \"placebo\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 11.3,\n            \"sd\": 1.2\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 0.7,\n            \"sd\": 0.8\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 8.0,\n            \"sd\": 2.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 25.0,\n            \"sd\": 3.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 10.0,\n            \"sd\": 2.0\n          },\n          \"seroconversion_pct\": 0.9\n        }\n      },\n      \"injection_site_reactions\": {\n        \"pain_pct\": 53.7,\n        \"erythema_pct\": 12.6,\n        \"swelling_pct\": 17.6,\n        \"induration_pct\": 4.4,\n        \"mean_pain_duration_hours\": 18.8\n      },\n      \"systemic_reactogenicity\": {\n        \"fever_pct\": 19.9,\n        \"fatigue_pct\": 38.1,\n        \"myalgia_pct\": 30.2,\n        \"headache_pct\": 27.5,\n        \"chills_pct\": 10.1\n      },\n      \"safety_labs\": {\n        \"wbc_k\": {\n          \"mean\": 7.1,\n          \"sd\": 1.3\n        },\n        \"lymphocyte_pct\": {\n          \"mean\": 32.0,\n          \"sd\": 5.2\n        },\n        \"neutrophil_pct\": {\n          \"mean\": 63.7,\n          \"sd\": 5.4\n        },\n        \"platelets_k\": {\n          \"mean\": 218,\n          \"sd\": 41\n        },\n        \"crp_mg_l\": {\n          \"mean\": 7.7,\n          \"sd\": 1.9\n        },\n        \"hemoglobin_g_dl\": {\n          \"mean\": 14.2,\n          \"sd\": 1.2\n        }\n      },\n      \"adverse_events\": [\n        {\n          \"ae_id\": \"VI-AE-0417\",\n          \"description\": \"lymphadenopathy\",\n          \"grade\": 2,\n          \"relatedness\": \"related\",\n          \"resolved\": true,\n          \"dose_group\": \"low_dose\"\n        },\n        {\n          \"ae_id\": \"VI-AE-0429\",\n          \"description\": \"nausea\",\n          \"grade\": 1,\n          \"relatedness\": \"possibly related\",\n          \"resolved\": true,\n          \"dose_group\": \"low_dose\"\n        },\n        {\n          \"ae_id\": \"VI-AE-0425\",\n          \"description\": \"malaise\",\n          \"grade\": 2,\n          \"relatedness\": \"possibly related\",\n          \"resolved\": true,\n          \"dose_group\": \"high_dose\"\n        }\n      ],\n      \"events\": [\n        \"Vaccination day 1: 21 subjects received scheduled dose\",\n        \"Immunology core lab QC report received\"\n      ],\n      \"notes\": \"Week 4: Immunogenicity assessments on schedule. 80 subjects enrolled across dose groups. Reactogenicity profiles consistent with prior weeks.\"\n    },\n    {\n      \"index\": 5,\n      \"date\": \"2024-04-01\",\n      \"theme\": \"vaccine_immunogenicity\",\n      \"enrollment\": {\n        \"total_enrolled\": 92,\n        \"active\": 90,\n        \"screen_failures_cumulative\": 9,\n        \"withdrawals_cumulative\": 2,\n        \"by_dose_group\": {\n          \"low_dose\": 21,\n          \"mid_dose\": 25,\n          \"high_dose\": 24,\n          \"placebo\": 22\n        }\n      },\n      \"immunogenicity_by_group\": {\n        \"low_dose\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 40.4,\n            \"sd\": 6.0\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 16.0,\n            \"sd\": 4.0\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 54.7,\n            \"sd\": 10.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 97.0,\n            \"sd\": 15.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 65.0,\n            \"sd\": 11.0\n          },\n          \"seroconversion_pct\": 17.1\n        },\n        \"mid_dose\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 57.4,\n            \"sd\": 9.6\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 30.2,\n            \"sd\": 6.4\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 98.3,\n            \"sd\": 16.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 140.0,\n            \"sd\": 24.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 98.0,\n            \"sd\": 18.0\n          },\n          \"seroconversion_pct\": 19.4\n        },\n        \"high_dose\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 75.4,\n            \"sd\": 13.2\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 37.1,\n            \"sd\": 8.8\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 129.5,\n            \"sd\": 22.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 201.0,\n            \"sd\": 33.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 129.0,\n            \"sd\": 24.0\n          },\n          \"seroconversion_pct\": 34.8\n        },\n        \"placebo\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 4.9,\n            \"sd\": 1.2\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 5.6,\n            \"sd\": 0.8\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 5.0,\n            \"sd\": 2.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 8.0,\n            \"sd\": 3.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 16.0,\n            \"sd\": 2.0\n          },\n          \"seroconversion_pct\": 5.4\n        }\n      },\n      \"injection_site_reactions\": {\n        \"pain_pct\": 52.9,\n        \"erythema_pct\": 26.9,\n        \"swelling_pct\": 7.8,\n        \"induration_pct\": 9.4,\n        \"mean_pain_duration_hours\": 23.0\n      },\n      \"systemic_reactogenicity\": {\n        \"fever_pct\": 21.4,\n        \"fatigue_pct\": 33.9,\n        \"myalgia_pct\": 34.2,\n        \"headache_pct\": 16.1,\n        \"chills_pct\": 14.3\n      },\n      \"safety_labs\": {\n        \"wbc_k\": {\n          \"mean\": 8.8,\n          \"sd\": 1.4\n        },\n        \"lymphocyte_pct\": {\n          \"mean\": 28.8,\n          \"sd\": 7.7\n        },\n        \"neutrophil_pct\": {\n          \"mean\": 58.6,\n          \"sd\": 6.5\n        },\n        \"platelets_k\": {\n          \"mean\": 244,\n          \"sd\": 38\n        },\n        \"crp_mg_l\": {\n          \"mean\": 1.6,\n          \"sd\": 1.7\n        },\n        \"hemoglobin_g_dl\": {\n          \"mean\": 13.4,\n          \"sd\": 0.8\n        }\n      },\n      \"adverse_events\": [\n        {\n          \"ae_id\": \"VI-AE-0507\",\n          \"description\": \"myalgia\",\n          \"grade\": 1,\n          \"relatedness\": \"possibly related\",\n          \"resolved\": true,\n          \"dose_group\": \"low_dose\"\n        },\n        {\n          \"ae_id\": \"VI-AE-0573\",\n          \"description\": \"lymphadenopathy\",\n          \"grade\": 1,\n          \"relatedness\": \"possibly related\",\n          \"resolved\": true,\n          \"dose_group\": \"high_dose\"\n        },\n        {\n          \"ae_id\": \"VI-AE-0595\",\n          \"description\": \"lymphadenopathy\",\n          \"grade\": 2,\n          \"relatedness\": \"possibly related\",\n          \"resolved\": true,\n          \"dose_group\": \"mid_dose\"\n        },\n        {\n          \"ae_id\": \"VI-AE-0591\",\n          \"description\": \"injection site pain\",\n          \"grade\": 2,\n          \"relatedness\": \"possibly related\",\n          \"resolved\": true,\n          \"dose_group\": \"mid_dose\"\n        }\n      ],\n      \"events\": [\n        \"Serology samples shipped to central immunology lab\",\n        \"Vaccination day 6: 17 subjects received scheduled dose\"\n      ],\n      \"notes\": \"Week 5: Immunogenicity assessments on schedule. 92 subjects enrolled across dose groups. Reactogenicity profiles consistent with prior weeks.\"\n    },\n    {\n      \"index\": 6,\n      \"date\": \"2024-04-08\",\n      \"theme\": \"vaccine_immunogenicity\",\n      \"enrollment\": {\n        \"total_enrolled\": 106,\n        \"active\": 105,\n        \"screen_failures_cumulative\": 10,\n        \"withdrawals_cumulative\": 1,\n        \"by_dose_group\": {\n          \"low_dose\": 27,\n          \"mid_dose\": 26,\n          \"high_dose\": 28,\n          \"placebo\": 25\n        }\n      },\n      \"immunogenicity_by_group\": {\n        \"low_dose\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 35.4,\n            \"sd\": 6.0\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 20.3,\n            \"sd\": 4.0\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 71.9,\n            \"sd\": 10.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 92.0,\n            \"sd\": 15.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 62.0,\n            \"sd\": 11.0\n          },\n          \"seroconversion_pct\": 17.9\n        },\n        \"mid_dose\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 64.4,\n            \"sd\": 9.6\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 32.2,\n            \"sd\": 6.4\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 104.8,\n            \"sd\": 16.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 156.0,\n            \"sd\": 24.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 105.0,\n            \"sd\": 18.0\n          },\n          \"seroconversion_pct\": 26.5\n        },\n        \"high_dose\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 93.0,\n            \"sd\": 13.2\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 41.0,\n            \"sd\": 8.8\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 141.8,\n            \"sd\": 22.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 212.0,\n            \"sd\": 33.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 151.0,\n            \"sd\": 24.0\n          },\n          \"seroconversion_pct\": 31.8\n        },\n        \"placebo\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 11.3,\n            \"sd\": 1.2\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 4.9,\n            \"sd\": 0.8\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 16.7,\n            \"sd\": 2.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 12.0,\n            \"sd\": 3.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 19.0,\n            \"sd\": 2.0\n          },\n          \"seroconversion_pct\": 3.6\n        }\n      },\n      \"injection_site_reactions\": {\n        \"pain_pct\": 61.8,\n        \"erythema_pct\": 13.9,\n        \"swelling_pct\": 16.7,\n        \"induration_pct\": 6.4,\n        \"mean_pain_duration_hours\": 19.6\n      },\n      \"systemic_reactogenicity\": {\n        \"fever_pct\": 21.2,\n        \"fatigue_pct\": 42.9,\n        \"myalgia_pct\": 31.4,\n        \"headache_pct\": 18.9,\n        \"chills_pct\": 5.7\n      },\n      \"safety_labs\": {\n        \"wbc_k\": {\n          \"mean\": 5.5,\n          \"sd\": 1.7\n        },\n        \"lymphocyte_pct\": {\n          \"mean\": 37.5,\n          \"sd\": 4.7\n        },\n        \"neutrophil_pct\": {\n          \"mean\": 57.9,\n          \"sd\": 7.9\n        },\n        \"platelets_k\": {\n          \"mean\": 220,\n          \"sd\": 40\n        },\n        \"crp_mg_l\": {\n          \"mean\": 7.5,\n          \"sd\": 0.6\n        },\n        \"hemoglobin_g_dl\": {\n          \"mean\": 13.7,\n          \"sd\": 1.3\n        }\n      },\n      \"adverse_events\": [\n        {\n          \"ae_id\": \"VI-AE-0627\",\n          \"description\": \"fatigue\",\n          \"grade\": 1,\n          \"relatedness\": \"related\",\n          \"resolved\": true,\n          \"dose_group\": \"mid_dose\"\n        },\n        {\n          \"ae_id\": \"VI-AE-0632\",\n          \"description\": \"lymphadenopathy\",\n          \"grade\": 2,\n          \"relatedness\": \"possibly related\",\n          \"resolved\": true,\n          \"dose_group\": \"mid_dose\"\n        },\n        {\n          \"ae_id\": \"VI-AE-0610\",\n          \"description\": \"arthralgia\",\n          \"grade\": 2,\n          \"relatedness\": \"related\",\n          \"resolved\": true,\n          \"dose_group\": \"low_dose\"\n        }\n      ],\n      \"events\": [\n        \"Serology samples shipped to central immunology lab\",\n        \"DSMB safety review teleconference completed\",\n        \"Serum sample aliquoting completed for 15 subjects\"\n      ],\n      \"notes\": \"Week 6: Immunogenicity assessments on schedule. 106 subjects enrolled across dose groups. Reactogenicity profiles consistent with prior weeks.\"\n    },\n    {\n      \"index\": 7,\n      \"date\": \"2024-04-15\",\n      \"theme\": \"vaccine_immunogenicity\",\n      \"enrollment\": {\n        \"total_enrolled\": 105,\n        \"active\": 103,\n        \"screen_failures_cumulative\": 12,\n        \"withdrawals_cumulative\": 2,\n        \"by_dose_group\": {\n          \"low_dose\": 25,\n          \"mid_dose\": 25,\n          \"high_dose\": 27,\n          \"placebo\": 28\n        }\n      },\n      \"immunogenicity_by_group\": {\n        \"low_dose\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 48.5,\n            \"sd\": 6.0\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 16.4,\n            \"sd\": 4.0\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 62.3,\n            \"sd\": 10.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 109.0,\n            \"sd\": 15.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 68.0,\n            \"sd\": 11.0\n          },\n          \"seroconversion_pct\": 21.1\n        },\n        \"mid_dose\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 73.5,\n            \"sd\": 9.6\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 29.0,\n            \"sd\": 6.4\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 115.2,\n            \"sd\": 16.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 165.0,\n            \"sd\": 24.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 125.0,\n            \"sd\": 18.0\n          },\n          \"seroconversion_pct\": 28.7\n        },\n        \"high_dose\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 100.6,\n            \"sd\": 13.2\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 42.0,\n            \"sd\": 8.8\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 147.4,\n            \"sd\": 22.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 235.0,\n            \"sd\": 33.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 162.0,\n            \"sd\": 24.0\n          },\n          \"seroconversion_pct\": 41.4\n        },\n        \"placebo\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 6.8,\n            \"sd\": 1.2\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 5.1,\n            \"sd\": 0.8\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 14.0,\n            \"sd\": 2.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 25.0,\n            \"sd\": 3.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 16.0,\n            \"sd\": 2.0\n          },\n          \"seroconversion_pct\": 5.5\n        }\n      },\n      \"injection_site_reactions\": {\n        \"pain_pct\": 50.9,\n        \"erythema_pct\": 28.9,\n        \"swelling_pct\": 9.9,\n        \"induration_pct\": 8.8,\n        \"mean_pain_duration_hours\": 34.2\n      },\n      \"systemic_reactogenicity\": {\n        \"fever_pct\": 16.6,\n        \"fatigue_pct\": 23.1,\n        \"myalgia_pct\": 27.9,\n        \"headache_pct\": 19.5,\n        \"chills_pct\": 14.4\n      },\n      \"safety_labs\": {\n        \"wbc_k\": {\n          \"mean\": 9.0,\n          \"sd\": 1.5\n        },\n        \"lymphocyte_pct\": {\n          \"mean\": 39.9,\n          \"sd\": 7.8\n        },\n        \"neutrophil_pct\": {\n          \"mean\": 56.0,\n          \"sd\": 6.5\n        },\n        \"platelets_k\": {\n          \"mean\": 237,\n          \"sd\": 43\n        },\n        \"crp_mg_l\": {\n          \"mean\": 5.5,\n          \"sd\": 1.6\n        },\n        \"hemoglobin_g_dl\": {\n          \"mean\": 13.9,\n          \"sd\": 0.8\n        }\n      },\n      \"adverse_events\": [\n        {\n          \"ae_id\": \"VI-AE-0771\",\n          \"description\": \"malaise\",\n          \"grade\": 1,\n          \"relatedness\": \"possibly related\",\n          \"resolved\": true,\n          \"dose_group\": \"high_dose\"\n        },\n        {\n          \"ae_id\": \"VI-AE-0765\",\n          \"description\": \"injection site pain\",\n          \"grade\": 1,\n          \"relatedness\": \"related\",\n          \"resolved\": true,\n          \"dose_group\": \"low_dose\"\n        },\n        {\n          \"ae_id\": \"VI-AE-0749\",\n          \"description\": \"headache\",\n          \"grade\": 2,\n          \"relatedness\": \"possibly related\",\n          \"resolved\": true,\n          \"dose_group\": \"mid_dose\"\n        },\n        {\n          \"ae_id\": \"VI-AE-0701\",\n          \"description\": \"fatigue\",\n          \"grade\": 1,\n          \"relatedness\": \"related\",\n          \"resolved\": true,\n          \"dose_group\": \"low_dose\"\n        }\n      ],\n      \"events\": [\n        \"Serum sample aliquoting completed for 20 subjects\",\n        \"Cold chain temperature log reviewed: all within -70C +/- 5C\"\n      ],\n      \"notes\": \"Week 7: Immunogenicity assessments on schedule. 105 subjects enrolled across dose groups. Reactogenicity profiles consistent with prior weeks.\"\n    },\n    {\n      \"index\": 8,\n      \"date\": \"2024-04-22\",\n      \"theme\": \"vaccine_immunogenicity\",\n      \"enrollment\": {\n        \"total_enrolled\": 107,\n        \"active\": 105,\n        \"screen_failures_cumulative\": 12,\n        \"withdrawals_cumulative\": 2,\n        \"by_dose_group\": {\n          \"low_dose\": 25,\n          \"mid_dose\": 27,\n          \"high_dose\": 26,\n          \"placebo\": 29\n        }\n      },\n      \"immunogenicity_by_group\": {\n        \"low_dose\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 45.6,\n            \"sd\": 6.0\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 17.8,\n            \"sd\": 4.0\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 74.3,\n            \"sd\": 10.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 121.0,\n            \"sd\": 15.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 82.0,\n            \"sd\": 11.0\n          },\n          \"seroconversion_pct\": 16.1\n        },\n        \"mid_dose\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 83.3,\n            \"sd\": 9.6\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 33.0,\n            \"sd\": 6.4\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 120.8,\n            \"sd\": 16.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 191.0,\n            \"sd\": 24.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 130.0,\n            \"sd\": 18.0\n          },\n          \"seroconversion_pct\": 36.0\n        },\n        \"high_dose\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 106.0,\n            \"sd\": 13.2\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 40.8,\n            \"sd\": 8.8\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 176.1,\n            \"sd\": 22.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 257.0,\n            \"sd\": 33.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 180.0,\n            \"sd\": 24.0\n          },\n          \"seroconversion_pct\": 45.0\n        },\n        \"placebo\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 5.9,\n            \"sd\": 1.2\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 3.4,\n            \"sd\": 0.8\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 10.9,\n            \"sd\": 2.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 21.0,\n            \"sd\": 3.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 17.0,\n            \"sd\": 2.0\n          },\n          \"seroconversion_pct\": 7.7\n        }\n      },\n      \"injection_site_reactions\": {\n        \"pain_pct\": 47.4,\n        \"erythema_pct\": 19.4,\n        \"swelling_pct\": 14.5,\n        \"induration_pct\": 8.8,\n        \"mean_pain_duration_hours\": 17.7\n      },\n      \"systemic_reactogenicity\": {\n        \"fever_pct\": 15.2,\n        \"fatigue_pct\": 31.9,\n        \"myalgia_pct\": 19.0,\n        \"headache_pct\": 26.4,\n        \"chills_pct\": 5.3\n      },\n      \"safety_labs\": {\n        \"wbc_k\": {\n          \"mean\": 7.2,\n          \"sd\": 1.8\n        },\n        \"lymphocyte_pct\": {\n          \"mean\": 26.0,\n          \"sd\": 5.8\n        },\n        \"neutrophil_pct\": {\n          \"mean\": 52.9,\n          \"sd\": 6.9\n        },\n        \"platelets_k\": {\n          \"mean\": 219,\n          \"sd\": 39\n        },\n        \"crp_mg_l\": {\n          \"mean\": 2.0,\n          \"sd\": 1.2\n        },\n        \"hemoglobin_g_dl\": {\n          \"mean\": 14.6,\n          \"sd\": 1.4\n        }\n      },\n      \"adverse_events\": [\n        {\n          \"ae_id\": \"VI-AE-0818\",\n          \"description\": \"lymphadenopathy\",\n          \"grade\": 2,\n          \"relatedness\": \"possibly related\",\n          \"resolved\": true,\n          \"dose_group\": \"high_dose\"\n        },\n        {\n          \"ae_id\": \"VI-AE-0817\",\n          \"description\": \"malaise\",\n          \"grade\": 2,\n          \"relatedness\": \"possibly related\",\n          \"resolved\": true,\n          \"dose_group\": \"mid_dose\"\n        }\n      ],\n      \"events\": [\n        \"Reactogenicity diary card collection rate: 95%\",\n        \"Vaccine lot VX-645 temperature excursion assessed: within acceptable range\"\n      ],\n      \"notes\": \"Week 8: Immunogenicity assessments on schedule. 107 subjects enrolled across dose groups. Reactogenicity profiles consistent with prior weeks.\"\n    },\n    {\n      \"index\": 9,\n      \"date\": \"2024-04-29\",\n      \"theme\": \"vaccine_immunogenicity\",\n      \"enrollment\": {\n        \"total_enrolled\": 106,\n        \"active\": 104,\n        \"screen_failures_cumulative\": 12,\n        \"withdrawals_cumulative\": 2,\n        \"by_dose_group\": {\n          \"low_dose\": 25,\n          \"mid_dose\": 25,\n          \"high_dose\": 28,\n          \"placebo\": 28\n        }\n      },\n      \"immunogenicity_by_group\": {\n        \"low_dose\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 56.0,\n            \"sd\": 6.0\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 19.1,\n            \"sd\": 4.0\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 94.3,\n            \"sd\": 10.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 136.0,\n            \"sd\": 15.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 97.0,\n            \"sd\": 11.0\n          },\n          \"seroconversion_pct\": 25.1\n        },\n        \"mid_dose\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 94.6,\n            \"sd\": 9.6\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 29.4,\n            \"sd\": 6.4\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 147.2,\n            \"sd\": 16.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 212.0,\n            \"sd\": 24.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 161.0,\n            \"sd\": 18.0\n          },\n          \"seroconversion_pct\": 32.4\n        },\n        \"high_dose\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 121.7,\n            \"sd\": 13.2\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 38.8,\n            \"sd\": 8.8\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 200.1,\n            \"sd\": 22.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 300.0,\n            \"sd\": 33.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 216.0,\n            \"sd\": 24.0\n          },\n          \"seroconversion_pct\": 51.1\n        },\n        \"placebo\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 6.5,\n            \"sd\": 1.2\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 3.5,\n            \"sd\": 0.8\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 17.2,\n            \"sd\": 2.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 25.0,\n            \"sd\": 3.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 25.0,\n            \"sd\": 2.0\n          },\n          \"seroconversion_pct\": 4.5\n        }\n      },\n      \"injection_site_reactions\": {\n        \"pain_pct\": 54.3,\n        \"erythema_pct\": 21.9,\n        \"swelling_pct\": 17.9,\n        \"induration_pct\": 7.8,\n        \"mean_pain_duration_hours\": 39.4\n      },\n      \"systemic_reactogenicity\": {\n        \"fever_pct\": 12.8,\n        \"fatigue_pct\": 40.6,\n        \"myalgia_pct\": 23.2,\n        \"headache_pct\": 29.7,\n        \"chills_pct\": 8.4\n      },\n      \"safety_labs\": {\n        \"wbc_k\": {\n          \"mean\": 6.5,\n          \"sd\": 1.7\n        },\n        \"lymphocyte_pct\": {\n          \"mean\": 25.0,\n          \"sd\": 4.1\n        },\n        \"neutrophil_pct\": {\n          \"mean\": 46.9,\n          \"sd\": 8.0\n        },\n        \"platelets_k\": {\n          \"mean\": 220,\n          \"sd\": 41\n        },\n        \"crp_mg_l\": {\n          \"mean\": 5.7,\n          \"sd\": 1.1\n        },\n        \"hemoglobin_g_dl\": {\n          \"mean\": 13.4,\n          \"sd\": 1.1\n        }\n      },\n      \"adverse_events\": [\n        {\n          \"ae_id\": \"VI-AE-0932\",\n          \"description\": \"myalgia\",\n          \"grade\": 1,\n          \"relatedness\": \"possibly related\",\n          \"resolved\": true,\n          \"dose_group\": \"low_dose\"\n        },\n        {\n          \"ae_id\": \"VI-AE-0962\",\n          \"description\": \"lymphadenopathy\",\n          \"grade\": 2,\n          \"relatedness\": \"possibly related\",\n          \"resolved\": true,\n          \"dose_group\": \"low_dose\"\n        },\n        {\n          \"ae_id\": \"VI-AE-0971\",\n          \"description\": \"chills\",\n          \"grade\": 1,\n          \"relatedness\": \"possibly related\",\n          \"resolved\": true,\n          \"dose_group\": \"mid_dose\"\n        }\n      ],\n      \"events\": [\n        \"T-cell assay batch B09 processed, results QC'd\",\n        \"DSMB safety review teleconference completed\"\n      ],\n      \"notes\": \"Week 9: Immunogenicity assessments on schedule. 106 subjects enrolled across dose groups. Reactogenicity profiles consistent with prior weeks.\"\n    },\n    {\n      \"index\": 10,\n      \"date\": \"2024-05-06\",\n      \"theme\": \"vaccine_immunogenicity\",\n      \"enrollment\": {\n        \"total_enrolled\": 107,\n        \"active\": 103,\n        \"screen_failures_cumulative\": 17,\n        \"withdrawals_cumulative\": 4,\n        \"by_dose_group\": {\n          \"low_dose\": 26,\n          \"mid_dose\": 26,\n          \"high_dose\": 26,\n          \"placebo\": 29\n        }\n      },\n      \"immunogenicity_by_group\": {\n        \"low_dose\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 63.5,\n            \"sd\": 6.0\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 16.4,\n            \"sd\": 4.0\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 105.4,\n            \"sd\": 10.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 156.0,\n            \"sd\": 15.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 114.0,\n            \"sd\": 11.0\n          },\n          \"seroconversion_pct\": 30.1\n        },\n        \"mid_dose\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 103.9,\n            \"sd\": 9.6\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 31.1,\n            \"sd\": 6.4\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 161.3,\n            \"sd\": 16.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 243.0,\n            \"sd\": 24.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 175.0,\n            \"sd\": 18.0\n          },\n          \"seroconversion_pct\": 37.0\n        },\n        \"high_dose\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 141.4,\n            \"sd\": 13.2\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 39.1,\n            \"sd\": 8.8\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 230.0,\n            \"sd\": 22.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 352.0,\n            \"sd\": 33.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 246.0,\n            \"sd\": 24.0\n          },\n          \"seroconversion_pct\": 56.7\n        },\n        \"placebo\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 17.6,\n            \"sd\": 1.2\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 2.4,\n            \"sd\": 0.8\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 21.8,\n            \"sd\": 2.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 34.0,\n            \"sd\": 3.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 23.0,\n            \"sd\": 2.0\n          },\n          \"seroconversion_pct\": 1.3\n        }\n      },\n      \"injection_site_reactions\": {\n        \"pain_pct\": 58.1,\n        \"erythema_pct\": 18.6,\n        \"swelling_pct\": 15.6,\n        \"induration_pct\": 8.1,\n        \"mean_pain_duration_hours\": 40.9\n      },\n      \"systemic_reactogenicity\": {\n        \"fever_pct\": 12.1,\n        \"fatigue_pct\": 25.9,\n        \"myalgia_pct\": 18.5,\n        \"headache_pct\": 15.8,\n        \"chills_pct\": 14.0\n      },\n      \"safety_labs\": {\n        \"wbc_k\": {\n          \"mean\": 7.1,\n          \"sd\": 1.7\n        },\n        \"lymphocyte_pct\": {\n          \"mean\": 39.6,\n          \"sd\": 5.4\n        },\n        \"neutrophil_pct\": {\n          \"mean\": 61.7,\n          \"sd\": 9.4\n        },\n        \"platelets_k\": {\n          \"mean\": 245,\n          \"sd\": 36\n        },\n        \"crp_mg_l\": {\n          \"mean\": 3.2,\n          \"sd\": 1.9\n        },\n        \"hemoglobin_g_dl\": {\n          \"mean\": 14.4,\n          \"sd\": 1.5\n        }\n      },\n      \"adverse_events\": [\n        {\n          \"ae_id\": \"VI-AE-1045\",\n          \"description\": \"myalgia\",\n          \"grade\": 2,\n          \"relatedness\": \"possibly related\",\n          \"resolved\": true,\n          \"dose_group\": \"mid_dose\"\n        },\n        {\n          \"ae_id\": \"VI-AE-1045\",\n          \"description\": \"injection site pain\",\n          \"grade\": 1,\n          \"relatedness\": \"possibly related\",\n          \"resolved\": true,\n          \"dose_group\": \"high_dose\"\n        },\n        {\n          \"ae_id\": \"VI-AE-1025\",\n          \"description\": \"fatigue\",\n          \"grade\": 1,\n          \"relatedness\": \"related\",\n          \"resolved\": true,\n          \"dose_group\": \"high_dose\"\n        }\n      ],\n      \"events\": [\n        \"Vaccination day 4: 12 subjects received scheduled dose\",\n        \"Cold chain temperature log reviewed: all within -70C +/- 5C\",\n        \"T-cell assay batch B10 processed, results QC'd\"\n      ],\n      \"notes\": \"Week 10: Immunogenicity assessments on schedule. 107 subjects enrolled across dose groups. Reactogenicity profiles consistent with prior weeks.\"\n    },\n    {\n      \"index\": 11,\n      \"date\": \"2024-05-13\",\n      \"theme\": \"vaccine_immunogenicity\",\n      \"enrollment\": {\n        \"total_enrolled\": 105,\n        \"active\": 101,\n        \"screen_failures_cumulative\": 19,\n        \"withdrawals_cumulative\": 4,\n        \"by_dose_group\": {\n          \"low_dose\": 25,\n          \"mid_dose\": 26,\n          \"high_dose\": 27,\n          \"placebo\": 27\n        }\n      },\n      \"immunogenicity_by_group\": {\n        \"low_dose\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 74.5,\n            \"sd\": 6.0\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 16.8,\n            \"sd\": 4.0\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 108.0,\n            \"sd\": 10.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 180.0,\n            \"sd\": 15.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 131.0,\n            \"sd\": 11.0\n          },\n          \"seroconversion_pct\": 32.4\n        },\n        \"mid_dose\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 115.0,\n            \"sd\": 9.6\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 27.9,\n            \"sd\": 6.4\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 185.7,\n            \"sd\": 16.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 283.0,\n            \"sd\": 24.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 192.0,\n            \"sd\": 18.0\n          },\n          \"seroconversion_pct\": 48.9\n        },\n        \"high_dose\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 162.4,\n            \"sd\": 13.2\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 38.4,\n            \"sd\": 8.8\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 250.2,\n            \"sd\": 22.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 392.0,\n            \"sd\": 33.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 263.0,\n            \"sd\": 24.0\n          },\n          \"seroconversion_pct\": 60.6\n        },\n        \"placebo\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 10.1,\n            \"sd\": 1.2\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 2.9,\n            \"sd\": 0.8\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 29.8,\n            \"sd\": 2.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 35.0,\n            \"sd\": 3.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 31.0,\n            \"sd\": 2.0\n          },\n          \"seroconversion_pct\": 8.4\n        }\n      },\n      \"injection_site_reactions\": {\n        \"pain_pct\": 43.4,\n        \"erythema_pct\": 21.1,\n        \"swelling_pct\": 5.5,\n        \"induration_pct\": 7.2,\n        \"mean_pain_duration_hours\": 27.6\n      },\n      \"systemic_reactogenicity\": {\n        \"fever_pct\": 22.3,\n        \"fatigue_pct\": 32.0,\n        \"myalgia_pct\": 23.1,\n        \"headache_pct\": 23.9,\n        \"chills_pct\": 8.7\n      },\n      \"safety_labs\": {\n        \"wbc_k\": {\n          \"mean\": 8.7,\n          \"sd\": 1.4\n        },\n        \"lymphocyte_pct\": {\n          \"mean\": 34.2,\n          \"sd\": 7.6\n        },\n        \"neutrophil_pct\": {\n          \"mean\": 63.8,\n          \"sd\": 8.3\n        },\n        \"platelets_k\": {\n          \"mean\": 245,\n          \"sd\": 42\n        },\n        \"crp_mg_l\": {\n          \"mean\": 3.6,\n          \"sd\": 0.6\n        },\n        \"hemoglobin_g_dl\": {\n          \"mean\": 13.1,\n          \"sd\": 1.1\n        }\n      },\n      \"adverse_events\": [\n        {\n          \"ae_id\": \"VI-AE-1137\",\n          \"description\": \"injection site pain\",\n          \"grade\": 1,\n          \"relatedness\": \"related\",\n          \"resolved\": true,\n          \"dose_group\": \"high_dose\"\n        },\n        {\n          \"ae_id\": \"VI-AE-1163\",\n          \"description\": \"malaise\",\n          \"grade\": 2,\n          \"relatedness\": \"possibly related\",\n          \"resolved\": true,\n          \"dose_group\": \"high_dose\"\n        },\n        {\n          \"ae_id\": \"VI-AE-1182\",\n          \"description\": \"malaise\",\n          \"grade\": 1,\n          \"relatedness\": \"possibly related\",\n          \"resolved\": true,\n          \"dose_group\": \"low_dose\"\n        }\n      ],\n      \"events\": [\n        \"Site 04 monitoring visit, 0 minor findings\",\n        \"DSMB safety review teleconference completed\",\n        \"Vaccination day 6: 22 subjects received scheduled dose\"\n      ],\n      \"notes\": \"Week 11: Immunogenicity assessments on schedule. 105 subjects enrolled across dose groups. Reactogenicity profiles consistent with prior weeks.\"\n    },\n    {\n      \"index\": 12,\n      \"date\": \"2024-05-20\",\n      \"theme\": \"vaccine_immunogenicity\",\n      \"enrollment\": {\n        \"total_enrolled\": 103,\n        \"active\": 99,\n        \"screen_failures_cumulative\": 15,\n        \"withdrawals_cumulative\": 4,\n        \"by_dose_group\": {\n          \"low_dose\": 24,\n          \"mid_dose\": 26,\n          \"high_dose\": 26,\n          \"placebo\": 27\n        }\n      },\n      \"immunogenicity_by_group\": {\n        \"low_dose\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 75.3,\n            \"sd\": 6.0\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 16.4,\n            \"sd\": 4.0\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 122.3,\n            \"sd\": 10.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 199.0,\n            \"sd\": 15.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 130.0,\n            \"sd\": 11.0\n          },\n          \"seroconversion_pct\": 33.6\n        },\n        \"mid_dose\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 130.2,\n            \"sd\": 9.6\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 30.3,\n            \"sd\": 6.4\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 211.4,\n            \"sd\": 16.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 317.0,\n            \"sd\": 24.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 216.0,\n            \"sd\": 18.0\n          },\n          \"seroconversion_pct\": 48.7\n        },\n        \"high_dose\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 180.8,\n            \"sd\": 13.2\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 38.6,\n            \"sd\": 8.8\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 276.6,\n            \"sd\": 22.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 420.0,\n            \"sd\": 33.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 298.0,\n            \"sd\": 24.0\n          },\n          \"seroconversion_pct\": 75.0\n        },\n        \"placebo\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 18.4,\n            \"sd\": 1.2\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 6.2,\n            \"sd\": 0.8\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 32.8,\n            \"sd\": 2.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 33.0,\n            \"sd\": 3.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 23.0,\n            \"sd\": 2.0\n          },\n          \"seroconversion_pct\": 4.0\n        }\n      },\n      \"injection_site_reactions\": {\n        \"pain_pct\": 49.7,\n        \"erythema_pct\": 12.1,\n        \"swelling_pct\": 14.6,\n        \"induration_pct\": 7.5,\n        \"mean_pain_duration_hours\": 35.1\n      },\n      \"systemic_reactogenicity\": {\n        \"fever_pct\": 15.1,\n        \"fatigue_pct\": 23.5,\n        \"myalgia_pct\": 31.6,\n        \"headache_pct\": 22.5,\n        \"chills_pct\": 10.3\n      },\n      \"safety_labs\": {\n        \"wbc_k\": {\n          \"mean\": 6.1,\n          \"sd\": 1.1\n        },\n        \"lymphocyte_pct\": {\n          \"mean\": 29.2,\n          \"sd\": 7.9\n        },\n        \"neutrophil_pct\": {\n          \"mean\": 45.1,\n          \"sd\": 6.7\n        },\n        \"platelets_k\": {\n          \"mean\": 246,\n          \"sd\": 39\n        },\n        \"crp_mg_l\": {\n          \"mean\": 5.5,\n          \"sd\": 0.9\n        },\n        \"hemoglobin_g_dl\": {\n          \"mean\": 13.6,\n          \"sd\": 1.5\n        }\n      },\n      \"adverse_events\": [\n        {\n          \"ae_id\": \"VI-AE-1235\",\n          \"description\": \"myalgia\",\n          \"grade\": 2,\n          \"relatedness\": \"possibly related\",\n          \"resolved\": true,\n          \"dose_group\": \"high_dose\"\n        },\n        {\n          \"ae_id\": \"VI-AE-1270\",\n          \"description\": \"malaise\",\n          \"grade\": 1,\n          \"relatedness\": \"possibly related\",\n          \"resolved\": true,\n          \"dose_group\": \"mid_dose\"\n        }\n      ],\n      \"events\": [\n        \"Reactogenicity diary card collection rate: 94%\",\n        \"Vaccination day 2: 19 subjects received scheduled dose\"\n      ],\n      \"notes\": \"Week 12: Immunogenicity assessments on schedule. 103 subjects enrolled across dose groups. Reactogenicity profiles consistent with prior weeks.\"\n    },\n    {\n      \"index\": 13,\n      \"date\": \"2024-05-27\",\n      \"theme\": \"vaccine_immunogenicity\",\n      \"enrollment\": {\n        \"total_enrolled\": 105,\n        \"active\": 100,\n        \"screen_failures_cumulative\": 17,\n        \"withdrawals_cumulative\": 5,\n        \"by_dose_group\": {\n          \"low_dose\": 24,\n          \"mid_dose\": 25,\n          \"high_dose\": 29,\n          \"placebo\": 27\n        }\n      },\n      \"immunogenicity_by_group\": {\n        \"low_dose\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 77.9,\n            \"sd\": 6.0\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 19.3,\n            \"sd\": 4.0\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 126.3,\n            \"sd\": 10.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 196.0,\n            \"sd\": 15.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 131.0,\n            \"sd\": 11.0\n          },\n          \"seroconversion_pct\": 27.9\n        },\n        \"mid_dose\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 123.6,\n            \"sd\": 9.6\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 27.4,\n            \"sd\": 6.4\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 197.1,\n            \"sd\": 16.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 306.0,\n            \"sd\": 24.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 210.0,\n            \"sd\": 18.0\n          },\n          \"seroconversion_pct\": 52.0\n        },\n        \"high_dose\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 172.1,\n            \"sd\": 13.2\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 41.1,\n            \"sd\": 8.8\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 274.0,\n            \"sd\": 22.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 414.0,\n            \"sd\": 33.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 285.0,\n            \"sd\": 24.0\n          },\n          \"seroconversion_pct\": 71.1\n        },\n        \"placebo\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 20.5,\n            \"sd\": 1.2\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 5.6,\n            \"sd\": 0.8\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 25.3,\n            \"sd\": 2.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 45.0,\n            \"sd\": 3.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 22.0,\n            \"sd\": 2.0\n          },\n          \"seroconversion_pct\": 9.5\n        }\n      },\n      \"injection_site_reactions\": {\n        \"pain_pct\": 35.6,\n        \"erythema_pct\": 23.6,\n        \"swelling_pct\": 6.5,\n        \"induration_pct\": 9.7,\n        \"mean_pain_duration_hours\": 16.6\n      },\n      \"systemic_reactogenicity\": {\n        \"fever_pct\": 11.5,\n        \"fatigue_pct\": 24.5,\n        \"myalgia_pct\": 24.0,\n        \"headache_pct\": 17.8,\n        \"chills_pct\": 8.6\n      },\n      \"safety_labs\": {\n        \"wbc_k\": {\n          \"mean\": 5.8,\n          \"sd\": 1.0\n        },\n        \"lymphocyte_pct\": {\n          \"mean\": 34.7,\n          \"sd\": 7.3\n        },\n        \"neutrophil_pct\": {\n          \"mean\": 57.5,\n          \"sd\": 6.0\n        },\n        \"platelets_k\": {\n          \"mean\": 226,\n          \"sd\": 41\n        },\n        \"crp_mg_l\": {\n          \"mean\": 5.1,\n          \"sd\": 2.0\n        },\n        \"hemoglobin_g_dl\": {\n          \"mean\": 13.1,\n          \"sd\": 1.2\n        }\n      },\n      \"adverse_events\": [\n        {\n          \"ae_id\": \"VI-AE-1328\",\n          \"description\": \"nausea\",\n          \"grade\": 1,\n          \"relatedness\": \"possibly related\",\n          \"resolved\": true,\n          \"dose_group\": \"high_dose\"\n        },\n        {\n          \"ae_id\": \"VI-AE-1347\",\n          \"description\": \"lymphadenopathy\",\n          \"grade\": 1,\n          \"relatedness\": \"possibly related\",\n          \"resolved\": true,\n          \"dose_group\": \"high_dose\"\n        },\n        {\n          \"ae_id\": \"VI-AE-1306\",\n          \"description\": \"malaise\",\n          \"grade\": 2,\n          \"relatedness\": \"possibly related\",\n          \"resolved\": true,\n          \"dose_group\": \"high_dose\"\n        },\n        {\n          \"ae_id\": \"VI-AE-1326\",\n          \"description\": \"fever\",\n          \"grade\": 2,\n          \"relatedness\": \"possibly related\",\n          \"resolved\": true,\n          \"dose_group\": \"mid_dose\"\n        }\n      ],\n      \"events\": [\n        \"DSMB safety review teleconference completed\",\n        \"Immunology core lab QC report received\"\n      ],\n      \"notes\": \"Week 13: Immunogenicity assessments on schedule. 105 subjects enrolled across dose groups. Reactogenicity profiles consistent with prior weeks.\"\n    },\n    {\n      \"index\": 14,\n      \"date\": \"2024-06-03\",\n      \"theme\": \"vaccine_immunogenicity\",\n      \"enrollment\": {\n        \"total_enrolled\": 106,\n        \"active\": 100,\n        \"screen_failures_cumulative\": 17,\n        \"withdrawals_cumulative\": 6,\n        \"by_dose_group\": {\n          \"low_dose\": 24,\n          \"mid_dose\": 27,\n          \"high_dose\": 26,\n          \"placebo\": 29\n        }\n      },\n      \"immunogenicity_by_group\": {\n        \"low_dose\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 74.0,\n            \"sd\": 6.0\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 18.3,\n            \"sd\": 4.0\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 124.6,\n            \"sd\": 10.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 186.0,\n            \"sd\": 15.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 124.0,\n            \"sd\": 11.0\n          },\n          \"seroconversion_pct\": 31.2\n        },\n        \"mid_dose\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 126.1,\n            \"sd\": 9.6\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 29.5,\n            \"sd\": 6.4\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 187.2,\n            \"sd\": 16.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 285.0,\n            \"sd\": 24.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 204.0,\n            \"sd\": 18.0\n          },\n          \"seroconversion_pct\": 53.2\n        },\n        \"high_dose\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 166.2,\n            \"sd\": 13.2\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 39.7,\n            \"sd\": 8.8\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 261.8,\n            \"sd\": 22.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 403.0,\n            \"sd\": 33.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 284.0,\n            \"sd\": 24.0\n          },\n          \"seroconversion_pct\": 63.0\n        },\n        \"placebo\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 15.5,\n            \"sd\": 1.2\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 6.7,\n            \"sd\": 0.8\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 20.9,\n            \"sd\": 2.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 35.0,\n            \"sd\": 3.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 30.0,\n            \"sd\": 2.0\n          },\n          \"seroconversion_pct\": 8.4\n        }\n      },\n      \"injection_site_reactions\": {\n        \"pain_pct\": 57.0,\n        \"erythema_pct\": 15.5,\n        \"swelling_pct\": 13.6,\n        \"induration_pct\": 10.0,\n        \"mean_pain_duration_hours\": 34.6\n      },\n      \"systemic_reactogenicity\": {\n        \"fever_pct\": 20.8,\n        \"fatigue_pct\": 42.4,\n        \"myalgia_pct\": 27.0,\n        \"headache_pct\": 16.6,\n        \"chills_pct\": 7.1\n      },\n      \"safety_labs\": {\n        \"wbc_k\": {\n          \"mean\": 5.5,\n          \"sd\": 1.9\n        },\n        \"lymphocyte_pct\": {\n          \"mean\": 34.0,\n          \"sd\": 5.5\n        },\n        \"neutrophil_pct\": {\n          \"mean\": 50.0,\n          \"sd\": 5.7\n        },\n        \"platelets_k\": {\n          \"mean\": 241,\n          \"sd\": 44\n        },\n        \"crp_mg_l\": {\n          \"mean\": 3.6,\n          \"sd\": 0.6\n        },\n        \"hemoglobin_g_dl\": {\n          \"mean\": 13.9,\n          \"sd\": 1.2\n        }\n      },\n      \"adverse_events\": [\n        {\n          \"ae_id\": \"VI-AE-1431\",\n          \"description\": \"injection site pain\",\n          \"grade\": 1,\n          \"relatedness\": \"possibly related\",\n          \"resolved\": true,\n          \"dose_group\": \"high_dose\"\n        },\n        {\n          \"ae_id\": \"VI-AE-1450\",\n          \"description\": \"arthralgia\",\n          \"grade\": 1,\n          \"relatedness\": \"related\",\n          \"resolved\": true,\n          \"dose_group\": \"low_dose\"\n        },\n        {\n          \"ae_id\": \"VI-AE-1414\",\n          \"description\": \"headache\",\n          \"grade\": 2,\n          \"relatedness\": \"possibly related\",\n          \"resolved\": true,\n          \"dose_group\": \"mid_dose\"\n        },\n        {\n          \"ae_id\": \"VI-AE-1498\",\n          \"description\": \"chills\",\n          \"grade\": 1,\n          \"relatedness\": \"related\",\n          \"resolved\": true,\n          \"dose_group\": \"high_dose\"\n        }\n      ],\n      \"events\": [\n        \"Serology samples shipped to central immunology lab\",\n        \"Cold chain temperature log reviewed: all within -70C +/- 5C\"\n      ],\n      \"notes\": \"Week 14: Immunogenicity assessments on schedule. 106 subjects enrolled across dose groups. Reactogenicity profiles consistent with prior weeks.\"\n    },\n    {\n      \"index\": 15,\n      \"date\": \"2024-06-10\",\n      \"theme\": \"vaccine_immunogenicity\",\n      \"enrollment\": {\n        \"total_enrolled\": 107,\n        \"active\": 103,\n        \"screen_failures_cumulative\": 18,\n        \"withdrawals_cumulative\": 4,\n        \"by_dose_group\": {\n          \"low_dose\": 25,\n          \"mid_dose\": 27,\n          \"high_dose\": 26,\n          \"placebo\": 29\n        }\n      },\n      \"immunogenicity_by_group\": {\n        \"low_dose\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 76.1,\n            \"sd\": 6.0\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 21.7,\n            \"sd\": 4.0\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 120.7,\n            \"sd\": 10.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 177.0,\n            \"sd\": 15.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 129.0,\n            \"sd\": 11.0\n          },\n          \"seroconversion_pct\": 29.8\n        },\n        \"mid_dose\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 117.8,\n            \"sd\": 9.6\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 27.5,\n            \"sd\": 6.4\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 181.5,\n            \"sd\": 16.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 290.0,\n            \"sd\": 24.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 207.0,\n            \"sd\": 18.0\n          },\n          \"seroconversion_pct\": 45.1\n        },\n        \"high_dose\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 159.6,\n            \"sd\": 13.2\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 43.6,\n            \"sd\": 8.8\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 263.7,\n            \"sd\": 22.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 390.0,\n            \"sd\": 33.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 278.0,\n            \"sd\": 24.0\n          },\n          \"seroconversion_pct\": 62.5\n        },\n        \"placebo\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 10.1,\n            \"sd\": 1.2\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 5.3,\n            \"sd\": 0.8\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 29.9,\n            \"sd\": 2.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 41.0,\n            \"sd\": 3.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 23.0,\n            \"sd\": 2.0\n          },\n          \"seroconversion_pct\": 8.2\n        }\n      },\n      \"injection_site_reactions\": {\n        \"pain_pct\": 48.3,\n        \"erythema_pct\": 23.8,\n        \"swelling_pct\": 15.7,\n        \"induration_pct\": 6.7,\n        \"mean_pain_duration_hours\": 27.0\n      },\n      \"systemic_reactogenicity\": {\n        \"fever_pct\": 11.9,\n        \"fatigue_pct\": 29.5,\n        \"myalgia_pct\": 26.1,\n        \"headache_pct\": 15.7,\n        \"chills_pct\": 14.7\n      },\n      \"safety_labs\": {\n        \"wbc_k\": {\n          \"mean\": 7.7,\n          \"sd\": 1.5\n        },\n        \"lymphocyte_pct\": {\n          \"mean\": 26.1,\n          \"sd\": 7.5\n        },\n        \"neutrophil_pct\": {\n          \"mean\": 64.4,\n          \"sd\": 6.6\n        },\n        \"platelets_k\": {\n          \"mean\": 218,\n          \"sd\": 43\n        },\n        \"crp_mg_l\": {\n          \"mean\": 3.8,\n          \"sd\": 1.9\n        },\n        \"hemoglobin_g_dl\": {\n          \"mean\": 13.6,\n          \"sd\": 1.4\n        }\n      },\n      \"adverse_events\": [\n        {\n          \"ae_id\": \"VI-AE-1587\",\n          \"description\": \"fatigue\",\n          \"grade\": 1,\n          \"relatedness\": \"possibly related\",\n          \"resolved\": true,\n          \"dose_group\": \"high_dose\"\n        },\n        {\n          \"ae_id\": \"VI-AE-1524\",\n          \"description\": \"fatigue\",\n          \"grade\": 2,\n          \"relatedness\": \"possibly related\",\n          \"resolved\": true,\n          \"dose_group\": \"mid_dose\"\n        }\n      ],\n      \"events\": [\n        \"Vaccination day 6: 22 subjects received scheduled dose\",\n        \"Immunology core lab QC report received\"\n      ],\n      \"notes\": \"Week 15: Immunogenicity assessments on schedule. 107 subjects enrolled across dose groups. Reactogenicity profiles consistent with prior weeks.\"\n    },\n    {\n      \"index\": 16,\n      \"date\": \"2024-06-17\",\n      \"theme\": \"vaccine_immunogenicity\",\n      \"enrollment\": {\n        \"total_enrolled\": 128,\n        \"active\": 121,\n        \"screen_failures_cumulative\": 23,\n        \"withdrawals_cumulative\": 7,\n        \"by_dose_group\": {\n          \"low_dose\": 31,\n          \"mid_dose\": 32,\n          \"high_dose\": 32,\n          \"placebo\": 33\n        }\n      },\n      \"immunogenicity_by_group\": {\n        \"low_dose\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 76.3,\n            \"sd\": 6.0\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 18.9,\n            \"sd\": 4.0\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 117.6,\n            \"sd\": 10.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 177.0,\n            \"sd\": 15.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 118.0,\n            \"sd\": 11.0\n          },\n          \"seroconversion_pct\": 28.1\n        },\n        \"mid_dose\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 115.9,\n            \"sd\": 9.6\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 27.1,\n            \"sd\": 6.4\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 189.8,\n            \"sd\": 16.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 270.0,\n            \"sd\": 24.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 203.0,\n            \"sd\": 18.0\n          },\n          \"seroconversion_pct\": 49.9\n        },\n        \"high_dose\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 155.2,\n            \"sd\": 13.2\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 40.0,\n            \"sd\": 8.8\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 257.9,\n            \"sd\": 22.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 380.0,\n            \"sd\": 33.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 267.0,\n            \"sd\": 24.0\n          },\n          \"seroconversion_pct\": 64.4\n        },\n        \"placebo\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 12.0,\n            \"sd\": 1.2\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 1.8,\n            \"sd\": 0.8\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 27.3,\n            \"sd\": 2.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 35.0,\n            \"sd\": 3.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 28.0,\n            \"sd\": 2.0\n          },\n          \"seroconversion_pct\": 10.2\n        }\n      },\n      \"injection_site_reactions\": {\n        \"pain_pct\": 50.9,\n        \"erythema_pct\": 25.4,\n        \"swelling_pct\": 12.2,\n        \"induration_pct\": 3.7,\n        \"mean_pain_duration_hours\": 33.0\n      },\n      \"systemic_reactogenicity\": {\n        \"fever_pct\": 18.8,\n        \"fatigue_pct\": 41.0,\n        \"myalgia_pct\": 26.6,\n        \"headache_pct\": 27.6,\n        \"chills_pct\": 6.9\n      },\n      \"safety_labs\": {\n        \"wbc_k\": {\n          \"mean\": 7.6,\n          \"sd\": 1.1\n        },\n        \"lymphocyte_pct\": {\n          \"mean\": 34.4,\n          \"sd\": 6.2\n        },\n        \"neutrophil_pct\": {\n          \"mean\": 61.1,\n          \"sd\": 5.2\n        },\n        \"platelets_k\": {\n          \"mean\": 229,\n          \"sd\": 41\n        },\n        \"crp_mg_l\": {\n          \"mean\": 6.3,\n          \"sd\": 0.6\n        },\n        \"hemoglobin_g_dl\": {\n          \"mean\": 14.8,\n          \"sd\": 1.1\n        }\n      },\n      \"adverse_events\": [\n        {\n          \"ae_id\": \"VI-AE-1658\",\n          \"description\": \"fever\",\n          \"grade\": 2,\n          \"relatedness\": \"possibly related\",\n          \"resolved\": true,\n          \"dose_group\": \"mid_dose\"\n        },\n        {\n          \"ae_id\": \"VI-AE-1626\",\n          \"description\": \"lymphadenopathy\",\n          \"grade\": 1,\n          \"relatedness\": \"possibly related\",\n          \"resolved\": true,\n          \"dose_group\": \"mid_dose\"\n        }\n      ],\n      \"events\": [\n        \"Vaccine lot VX-825 temperature excursion assessed: within acceptable range\",\n        \"Immunology core lab QC report received\"\n      ],\n      \"notes\": \"Week 16: Immunogenicity assessments on schedule. 128 subjects enrolled across dose groups. Reactogenicity profiles consistent with prior weeks.\"\n    },\n    {\n      \"index\": 17,\n      \"date\": \"2024-06-24\",\n      \"theme\": \"vaccine_immunogenicity\",\n      \"enrollment\": {\n        \"total_enrolled\": 126,\n        \"active\": 119,\n        \"screen_failures_cumulative\": 25,\n        \"withdrawals_cumulative\": 7,\n        \"by_dose_group\": {\n          \"low_dose\": 31,\n          \"mid_dose\": 30,\n          \"high_dose\": 33,\n          \"placebo\": 32\n        }\n      },\n      \"immunogenicity_by_group\": {\n        \"low_dose\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 71.4,\n            \"sd\": 6.0\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 20.6,\n            \"sd\": 4.0\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 105.5,\n            \"sd\": 10.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 169.0,\n            \"sd\": 15.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 122.0,\n            \"sd\": 11.0\n          },\n          \"seroconversion_pct\": 32.9\n        },\n        \"mid_dose\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 108.4,\n            \"sd\": 9.6\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 29.3,\n            \"sd\": 6.4\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 186.2,\n            \"sd\": 16.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 270.0,\n            \"sd\": 24.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 192.0,\n            \"sd\": 18.0\n          },\n          \"seroconversion_pct\": 44.0\n        },\n        \"high_dose\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 150.2,\n            \"sd\": 13.2\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 39.5,\n            \"sd\": 8.8\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 245.1,\n            \"sd\": 22.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 379.0,\n            \"sd\": 33.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 254.0,\n            \"sd\": 24.0\n          },\n          \"seroconversion_pct\": 58.8\n        },\n        \"placebo\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 16.1,\n            \"sd\": 1.2\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 6.2,\n            \"sd\": 0.8\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 18.0,\n            \"sd\": 2.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 35.0,\n            \"sd\": 3.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 29.0,\n            \"sd\": 2.0\n          },\n          \"seroconversion_pct\": 6.5\n        }\n      },\n      \"injection_site_reactions\": {\n        \"pain_pct\": 37.5,\n        \"erythema_pct\": 19.9,\n        \"swelling_pct\": 18.6,\n        \"induration_pct\": 7.5,\n        \"mean_pain_duration_hours\": 33.5\n      },\n      \"systemic_reactogenicity\": {\n        \"fever_pct\": 17.4,\n        \"fatigue_pct\": 33.5,\n        \"myalgia_pct\": 27.9,\n        \"headache_pct\": 25.0,\n        \"chills_pct\": 8.7\n      },\n      \"safety_labs\": {\n        \"wbc_k\": {\n          \"mean\": 7.0,\n          \"sd\": 1.5\n        },\n        \"lymphocyte_pct\": {\n          \"mean\": 30.1,\n          \"sd\": 7.7\n        },\n        \"neutrophil_pct\": {\n          \"mean\": 49.5,\n          \"sd\": 7.7\n        },\n        \"platelets_k\": {\n          \"mean\": 241,\n          \"sd\": 40\n        },\n        \"crp_mg_l\": {\n          \"mean\": 5.1,\n          \"sd\": 1.6\n        },\n        \"hemoglobin_g_dl\": {\n          \"mean\": 13.7,\n          \"sd\": 0.9\n        }\n      },\n      \"adverse_events\": [\n        {\n          \"ae_id\": \"VI-AE-1745\",\n          \"description\": \"lymphadenopathy\",\n          \"grade\": 2,\n          \"relatedness\": \"possibly related\",\n          \"resolved\": true,\n          \"dose_group\": \"high_dose\"\n        },\n        {\n          \"ae_id\": \"VI-AE-1743\",\n          \"description\": \"fatigue\",\n          \"grade\": 2,\n          \"relatedness\": \"possibly related\",\n          \"resolved\": true,\n          \"dose_group\": \"high_dose\"\n        },\n        {\n          \"ae_id\": \"VI-AE-1715\",\n          \"description\": \"chills\",\n          \"grade\": 1,\n          \"relatedness\": \"related\",\n          \"resolved\": true,\n          \"dose_group\": \"low_dose\"\n        },\n        {\n          \"ae_id\": \"VI-AE-1782\",\n          \"description\": \"malaise\",\n          \"grade\": 1,\n          \"relatedness\": \"possibly related\",\n          \"resolved\": true,\n          \"dose_group\": \"low_dose\"\n        }\n      ],\n      \"events\": [\n        \"Vaccine lot VX-857 temperature excursion assessed: within acceptable range\",\n        \"Vaccine lot VX-943 temperature excursion assessed: within acceptable range\"\n      ],\n      \"notes\": \"Week 17: Immunogenicity assessments on schedule. 126 subjects enrolled across dose groups. Reactogenicity profiles consistent with prior weeks.\"\n    },\n    {\n      \"index\": 18,\n      \"date\": \"2024-07-01\",\n      \"theme\": \"vaccine_immunogenicity\",\n      \"enrollment\": {\n        \"total_enrolled\": 124,\n        \"active\": 117,\n        \"screen_failures_cumulative\": 31,\n        \"withdrawals_cumulative\": 7,\n        \"by_dose_group\": {\n          \"low_dose\": 29,\n          \"mid_dose\": 31,\n          \"high_dose\": 32,\n          \"placebo\": 32\n        }\n      },\n      \"immunogenicity_by_group\": {\n        \"low_dose\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 72.1,\n            \"sd\": 6.0\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 17.8,\n            \"sd\": 4.0\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 115.7,\n            \"sd\": 10.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 164.0,\n            \"sd\": 15.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 118.0,\n            \"sd\": 11.0\n          },\n          \"seroconversion_pct\": 30.5\n        },\n        \"mid_dose\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 108.4,\n            \"sd\": 9.6\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 29.4,\n            \"sd\": 6.4\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 175.5,\n            \"sd\": 16.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 259.0,\n            \"sd\": 24.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 192.0,\n            \"sd\": 18.0\n          },\n          \"seroconversion_pct\": 44.5\n        },\n        \"high_dose\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 149.7,\n            \"sd\": 13.2\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 41.4,\n            \"sd\": 8.8\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 240.2,\n            \"sd\": 22.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 363.0,\n            \"sd\": 33.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 249.0,\n            \"sd\": 24.0\n          },\n          \"seroconversion_pct\": 63.8\n        },\n        \"placebo\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 10.4,\n            \"sd\": 1.2\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 4.1,\n            \"sd\": 0.8\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 21.8,\n            \"sd\": 2.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 39.0,\n            \"sd\": 3.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 18.0,\n            \"sd\": 2.0\n          },\n          \"seroconversion_pct\": 1.2\n        }\n      },\n      \"injection_site_reactions\": {\n        \"pain_pct\": 35.6,\n        \"erythema_pct\": 23.4,\n        \"swelling_pct\": 11.5,\n        \"induration_pct\": 7.7,\n        \"mean_pain_duration_hours\": 17.2\n      },\n      \"systemic_reactogenicity\": {\n        \"fever_pct\": 16.1,\n        \"fatigue_pct\": 28.4,\n        \"myalgia_pct\": 20.3,\n        \"headache_pct\": 25.5,\n        \"chills_pct\": 5.7\n      },\n      \"safety_labs\": {\n        \"wbc_k\": {\n          \"mean\": 8.7,\n          \"sd\": 2.0\n        },\n        \"lymphocyte_pct\": {\n          \"mean\": 33.9,\n          \"sd\": 6.1\n        },\n        \"neutrophil_pct\": {\n          \"mean\": 55.2,\n          \"sd\": 8.3\n        },\n        \"platelets_k\": {\n          \"mean\": 226,\n          \"sd\": 39\n        },\n        \"crp_mg_l\": {\n          \"mean\": 2.3,\n          \"sd\": 0.6\n        },\n        \"hemoglobin_g_dl\": {\n          \"mean\": 13.8,\n          \"sd\": 1.3\n        }\n      },\n      \"adverse_events\": [\n        {\n          \"ae_id\": \"VI-AE-1847\",\n          \"description\": \"arthralgia\",\n          \"grade\": 1,\n          \"relatedness\": \"possibly related\",\n          \"resolved\": true,\n          \"dose_group\": \"low_dose\"\n        },\n        {\n          \"ae_id\": \"VI-AE-1879\",\n          \"description\": \"fatigue\",\n          \"grade\": 2,\n          \"relatedness\": \"related\",\n          \"resolved\": true,\n          \"dose_group\": \"high_dose\"\n        },\n        {\n          \"ae_id\": \"VI-AE-1884\",\n          \"description\": \"chills\",\n          \"grade\": 1,\n          \"relatedness\": \"possibly related\",\n          \"resolved\": true,\n          \"dose_group\": \"high_dose\"\n        }\n      ],\n      \"events\": [\n        \"DSMB safety review teleconference completed\",\n        \"Serum sample aliquoting completed for 18 subjects\"\n      ],\n      \"notes\": \"Week 18: Immunogenicity assessments on schedule. 124 subjects enrolled across dose groups. Reactogenicity profiles consistent with prior weeks.\"\n    },\n    {\n      \"index\": 19,\n      \"date\": \"2024-07-08\",\n      \"theme\": \"vaccine_immunogenicity\",\n      \"enrollment\": {\n        \"total_enrolled\": 125,\n        \"active\": 118,\n        \"screen_failures_cumulative\": 32,\n        \"withdrawals_cumulative\": 7,\n        \"by_dose_group\": {\n          \"low_dose\": 29,\n          \"mid_dose\": 32,\n          \"high_dose\": 32,\n          \"placebo\": 32\n        }\n      },\n      \"immunogenicity_by_group\": {\n        \"low_dose\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 61.2,\n            \"sd\": 6.0\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 17.2,\n            \"sd\": 4.0\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 110.5,\n            \"sd\": 10.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 168.0,\n            \"sd\": 15.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 120.0,\n            \"sd\": 11.0\n          },\n          \"seroconversion_pct\": 22.4\n        },\n        \"mid_dose\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 107.3,\n            \"sd\": 9.6\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 32.1,\n            \"sd\": 6.4\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 171.3,\n            \"sd\": 16.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 252.0,\n            \"sd\": 24.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 183.0,\n            \"sd\": 18.0\n          },\n          \"seroconversion_pct\": 43.1\n        },\n        \"high_dose\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 147.3,\n            \"sd\": 13.2\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 39.1,\n            \"sd\": 8.8\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 229.3,\n            \"sd\": 22.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 350.0,\n            \"sd\": 33.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 244.0,\n            \"sd\": 24.0\n          },\n          \"seroconversion_pct\": 55.5\n        },\n        \"placebo\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 13.0,\n            \"sd\": 1.2\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 0.8,\n            \"sd\": 0.8\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 23.0,\n            \"sd\": 2.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 39.0,\n            \"sd\": 3.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 23.0,\n            \"sd\": 2.0\n          },\n          \"seroconversion_pct\": 1.7\n        }\n      },\n      \"injection_site_reactions\": {\n        \"pain_pct\": 51.7,\n        \"erythema_pct\": 26.0,\n        \"swelling_pct\": 15.0,\n        \"induration_pct\": 8.5,\n        \"mean_pain_duration_hours\": 31.5\n      },\n      \"systemic_reactogenicity\": {\n        \"fever_pct\": 16.3,\n        \"fatigue_pct\": 42.7,\n        \"myalgia_pct\": 29.4,\n        \"headache_pct\": 23.2,\n        \"chills_pct\": 14.0\n      },\n      \"safety_labs\": {\n        \"wbc_k\": {\n          \"mean\": 8.4,\n          \"sd\": 1.8\n        },\n        \"lymphocyte_pct\": {\n          \"mean\": 25.7,\n          \"sd\": 5.2\n        },\n        \"neutrophil_pct\": {\n          \"mean\": 54.4,\n          \"sd\": 5.6\n        },\n        \"platelets_k\": {\n          \"mean\": 220,\n          \"sd\": 39\n        },\n        \"crp_mg_l\": {\n          \"mean\": 7.4,\n          \"sd\": 0.8\n        },\n        \"hemoglobin_g_dl\": {\n          \"mean\": 13.1,\n          \"sd\": 1.5\n        }\n      },\n      \"adverse_events\": [\n        {\n          \"ae_id\": \"VI-AE-1934\",\n          \"description\": \"lymphadenopathy\",\n          \"grade\": 1,\n          \"relatedness\": \"possibly related\",\n          \"resolved\": true,\n          \"dose_group\": \"high_dose\"\n        },\n        {\n          \"ae_id\": \"VI-AE-1973\",\n          \"description\": \"headache\",\n          \"grade\": 1,\n          \"relatedness\": \"possibly related\",\n          \"resolved\": true,\n          \"dose_group\": \"mid_dose\"\n        },\n        {\n          \"ae_id\": \"VI-AE-1920\",\n          \"description\": \"malaise\",\n          \"grade\": 2,\n          \"relatedness\": \"related\",\n          \"resolved\": true,\n          \"dose_group\": \"high_dose\"\n        },\n        {\n          \"ae_id\": \"VI-AE-1954\",\n          \"description\": \"fatigue\",\n          \"grade\": 1,\n          \"relatedness\": \"related\",\n          \"resolved\": true,\n          \"dose_group\": \"mid_dose\"\n        },\n        {\n          \"ae_id\": \"VI-AE-1911\",\n          \"description\": \"injection site pain\",\n          \"grade\": 2,\n          \"relatedness\": \"possibly related\",\n          \"resolved\": true,\n          \"dose_group\": \"mid_dose\"\n        }\n      ],\n      \"events\": [\n        \"Serology samples shipped to central immunology lab\",\n        \"Vaccination day 2: 12 subjects received scheduled dose\"\n      ],\n      \"notes\": \"Week 19: Immunogenicity assessments on schedule. 125 subjects enrolled across dose groups. Reactogenicity profiles consistent with prior weeks.\"\n    },\n    {\n      \"index\": 20,\n      \"date\": \"2024-07-15\",\n      \"theme\": \"vaccine_immunogenicity\",\n      \"enrollment\": {\n        \"total_enrolled\": 126,\n        \"active\": 117,\n        \"screen_failures_cumulative\": 35,\n        \"withdrawals_cumulative\": 9,\n        \"by_dose_group\": {\n          \"low_dose\": 30,\n          \"mid_dose\": 31,\n          \"high_dose\": 31,\n          \"placebo\": 34\n        }\n      },\n      \"immunogenicity_by_group\": {\n        \"low_dose\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 64.1,\n            \"sd\": 6.0\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 18.9,\n            \"sd\": 4.0\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 96.6,\n            \"sd\": 10.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 161.0,\n            \"sd\": 15.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 111.0,\n            \"sd\": 11.0\n          },\n          \"seroconversion_pct\": 29.5\n        },\n        \"mid_dose\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 106.8,\n            \"sd\": 9.6\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 29.9,\n            \"sd\": 6.4\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 169.4,\n            \"sd\": 16.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 246.0,\n            \"sd\": 24.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 179.0,\n            \"sd\": 18.0\n          },\n          \"seroconversion_pct\": 42.5\n        },\n        \"high_dose\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 140.6,\n            \"sd\": 13.2\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 41.9,\n            \"sd\": 8.8\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 222.9,\n            \"sd\": 22.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 329.0,\n            \"sd\": 33.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 242.0,\n            \"sd\": 24.0\n          },\n          \"seroconversion_pct\": 53.7\n        },\n        \"placebo\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 15.3,\n            \"sd\": 1.2\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 3.1,\n            \"sd\": 0.8\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 19.1,\n            \"sd\": 2.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 39.0,\n            \"sd\": 3.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 28.0,\n            \"sd\": 2.0\n          },\n          \"seroconversion_pct\": 6.7\n        }\n      },\n      \"injection_site_reactions\": {\n        \"pain_pct\": 55.1,\n        \"erythema_pct\": 23.9,\n        \"swelling_pct\": 11.5,\n        \"induration_pct\": 10.5,\n        \"mean_pain_duration_hours\": 34.3\n      },\n      \"systemic_reactogenicity\": {\n        \"fever_pct\": 16.4,\n        \"fatigue_pct\": 21.9,\n        \"myalgia_pct\": 31.5,\n        \"headache_pct\": 23.0,\n        \"chills_pct\": 11.5\n      },\n      \"safety_labs\": {\n        \"wbc_k\": {\n          \"mean\": 5.7,\n          \"sd\": 1.7\n        },\n        \"lymphocyte_pct\": {\n          \"mean\": 38.6,\n          \"sd\": 6.7\n        },\n        \"neutrophil_pct\": {\n          \"mean\": 51.5,\n          \"sd\": 8.0\n        },\n        \"platelets_k\": {\n          \"mean\": 225,\n          \"sd\": 44\n        },\n        \"crp_mg_l\": {\n          \"mean\": 6.9,\n          \"sd\": 1.0\n        },\n        \"hemoglobin_g_dl\": {\n          \"mean\": 14.7,\n          \"sd\": 1.2\n        }\n      },\n      \"adverse_events\": [\n        {\n          \"ae_id\": \"VI-AE-2068\",\n          \"description\": \"chills\",\n          \"grade\": 2,\n          \"relatedness\": \"possibly related\",\n          \"resolved\": true,\n          \"dose_group\": \"high_dose\"\n        },\n        {\n          \"ae_id\": \"VI-AE-2023\",\n          \"description\": \"headache\",\n          \"grade\": 1,\n          \"relatedness\": \"related\",\n          \"resolved\": true,\n          \"dose_group\": \"high_dose\"\n        },\n        {\n          \"ae_id\": \"VI-AE-2009\",\n          \"description\": \"malaise\",\n          \"grade\": 1,\n          \"relatedness\": \"possibly related\",\n          \"resolved\": true,\n          \"dose_group\": \"low_dose\"\n        },\n        {\n          \"ae_id\": \"VI-AE-2054\",\n          \"description\": \"nausea\",\n          \"grade\": 2,\n          \"relatedness\": \"possibly related\",\n          \"resolved\": true,\n          \"dose_group\": \"low_dose\"\n        }\n      ],\n      \"events\": [\n        \"DSMB safety review teleconference completed\",\n        \"Reactogenicity diary card collection rate: 95%\",\n        \"Site 03 monitoring visit, 3 minor findings\"\n      ],\n      \"notes\": \"Week 20: Immunogenicity assessments on schedule. 126 subjects enrolled across dose groups. Reactogenicity profiles consistent with prior weeks.\"\n    },\n    {\n      \"index\": 21,\n      \"date\": \"2024-07-22\",\n      \"theme\": \"vaccine_immunogenicity\",\n      \"enrollment\": {\n        \"total_enrolled\": 128,\n        \"active\": 121,\n        \"screen_failures_cumulative\": 34,\n        \"withdrawals_cumulative\": 7,\n        \"by_dose_group\": {\n          \"low_dose\": 31,\n          \"mid_dose\": 31,\n          \"high_dose\": 33,\n          \"placebo\": 33\n        }\n      },\n      \"immunogenicity_by_group\": {\n        \"low_dose\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 58.5,\n            \"sd\": 6.0\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 17.3,\n            \"sd\": 4.0\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 96.3,\n            \"sd\": 10.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 158.0,\n            \"sd\": 15.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 102.0,\n            \"sd\": 11.0\n          },\n          \"seroconversion_pct\": 27.6\n        },\n        \"mid_dose\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 99.0,\n            \"sd\": 9.6\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 28.8,\n            \"sd\": 6.4\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 154.1,\n            \"sd\": 16.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 235.0,\n            \"sd\": 24.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 171.0,\n            \"sd\": 18.0\n          },\n          \"seroconversion_pct\": 40.5\n        },\n        \"high_dose\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 133.7,\n            \"sd\": 13.2\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 44.0,\n            \"sd\": 8.8\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 219.7,\n            \"sd\": 22.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 334.0,\n            \"sd\": 33.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 227.0,\n            \"sd\": 24.0\n          },\n          \"seroconversion_pct\": 58.0\n        },\n        \"placebo\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 14.9,\n            \"sd\": 1.2\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 5.3,\n            \"sd\": 0.8\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 15.4,\n            \"sd\": 2.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 36.0,\n            \"sd\": 3.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 13.0,\n            \"sd\": 2.0\n          },\n          \"seroconversion_pct\": 6.8\n        }\n      },\n      \"injection_site_reactions\": {\n        \"pain_pct\": 43.2,\n        \"erythema_pct\": 28.9,\n        \"swelling_pct\": 19.6,\n        \"induration_pct\": 3.6,\n        \"mean_pain_duration_hours\": 21.8\n      },\n      \"systemic_reactogenicity\": {\n        \"fever_pct\": 21.8,\n        \"fatigue_pct\": 20.5,\n        \"myalgia_pct\": 23.5,\n        \"headache_pct\": 15.2,\n        \"chills_pct\": 12.5\n      },\n      \"safety_labs\": {\n        \"wbc_k\": {\n          \"mean\": 6.2,\n          \"sd\": 1.6\n        },\n        \"lymphocyte_pct\": {\n          \"mean\": 27.0,\n          \"sd\": 5.2\n        },\n        \"neutrophil_pct\": {\n          \"mean\": 52.2,\n          \"sd\": 8.2\n        },\n        \"platelets_k\": {\n          \"mean\": 242,\n          \"sd\": 41\n        },\n        \"crp_mg_l\": {\n          \"mean\": 3.1,\n          \"sd\": 1.2\n        },\n        \"hemoglobin_g_dl\": {\n          \"mean\": 13.6,\n          \"sd\": 1.2\n        }\n      },\n      \"adverse_events\": [\n        {\n          \"ae_id\": \"VI-AE-2166\",\n          \"description\": \"myalgia\",\n          \"grade\": 2,\n          \"relatedness\": \"related\",\n          \"resolved\": true,\n          \"dose_group\": \"low_dose\"\n        },\n        {\n          \"ae_id\": \"VI-AE-2141\",\n          \"description\": \"malaise\",\n          \"grade\": 1,\n          \"relatedness\": \"related\",\n          \"resolved\": true,\n          \"dose_group\": \"mid_dose\"\n        }\n      ],\n      \"events\": [\n        \"Vaccine lot VX-877 temperature excursion assessed: within acceptable range\",\n        \"Reactogenicity diary card collection rate: 96%\",\n        \"Vaccination day 1: 25 subjects received scheduled dose\"\n      ],\n      \"notes\": \"Week 21: Immunogenicity assessments on schedule. 128 subjects enrolled across dose groups. Reactogenicity profiles consistent with prior weeks.\"\n    },\n    {\n      \"index\": 22,\n      \"date\": \"2024-07-29\",\n      \"theme\": \"vaccine_immunogenicity\",\n      \"enrollment\": {\n        \"total_enrolled\": 125,\n        \"active\": 116,\n        \"screen_failures_cumulative\": 30,\n        \"withdrawals_cumulative\": 9,\n        \"by_dose_group\": {\n          \"low_dose\": 29,\n          \"mid_dose\": 31,\n          \"high_dose\": 32,\n          \"placebo\": 33\n        }\n      },\n      \"immunogenicity_by_group\": {\n        \"low_dose\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 59.3,\n            \"sd\": 6.0\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 16.1,\n            \"sd\": 4.0\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 96.7,\n            \"sd\": 10.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 146.0,\n            \"sd\": 15.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 102.0,\n            \"sd\": 11.0\n          },\n          \"seroconversion_pct\": 27.5\n        },\n        \"mid_dose\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 97.2,\n            \"sd\": 9.6\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 30.3,\n            \"sd\": 6.4\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 153.1,\n            \"sd\": 16.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 236.0,\n            \"sd\": 24.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 166.0,\n            \"sd\": 18.0\n          },\n          \"seroconversion_pct\": 41.6\n        },\n        \"high_dose\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 136.3,\n            \"sd\": 13.2\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 43.9,\n            \"sd\": 8.8\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 210.0,\n            \"sd\": 22.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 308.0,\n            \"sd\": 33.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 224.0,\n            \"sd\": 24.0\n          },\n          \"seroconversion_pct\": 51.7\n        },\n        \"placebo\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 7.0,\n            \"sd\": 1.2\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 5.9,\n            \"sd\": 0.8\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 11.2,\n            \"sd\": 2.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 20.0,\n            \"sd\": 3.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 14.0,\n            \"sd\": 2.0\n          },\n          \"seroconversion_pct\": 4.3\n        }\n      },\n      \"injection_site_reactions\": {\n        \"pain_pct\": 36.1,\n        \"erythema_pct\": 29.8,\n        \"swelling_pct\": 19.6,\n        \"induration_pct\": 5.5,\n        \"mean_pain_duration_hours\": 32.5\n      },\n      \"systemic_reactogenicity\": {\n        \"fever_pct\": 11.0,\n        \"fatigue_pct\": 28.3,\n        \"myalgia_pct\": 20.3,\n        \"headache_pct\": 23.2,\n        \"chills_pct\": 12.5\n      },\n      \"safety_labs\": {\n        \"wbc_k\": {\n          \"mean\": 8.9,\n          \"sd\": 1.4\n        },\n        \"lymphocyte_pct\": {\n          \"mean\": 37.5,\n          \"sd\": 5.4\n        },\n        \"neutrophil_pct\": {\n          \"mean\": 47.8,\n          \"sd\": 9.5\n        },\n        \"platelets_k\": {\n          \"mean\": 253,\n          \"sd\": 40\n        },\n        \"crp_mg_l\": {\n          \"mean\": 7.1,\n          \"sd\": 1.3\n        },\n        \"hemoglobin_g_dl\": {\n          \"mean\": 13.8,\n          \"sd\": 1.1\n        }\n      },\n      \"adverse_events\": [\n        {\n          \"ae_id\": \"VI-AE-2255\",\n          \"description\": \"myalgia\",\n          \"grade\": 1,\n          \"relatedness\": \"related\",\n          \"resolved\": true,\n          \"dose_group\": \"mid_dose\"\n        },\n        {\n          \"ae_id\": \"VI-AE-2265\",\n          \"description\": \"fever\",\n          \"grade\": 1,\n          \"relatedness\": \"possibly related\",\n          \"resolved\": true,\n          \"dose_group\": \"high_dose\"\n        }\n      ],\n      \"events\": [\n        \"Serology samples shipped to central immunology lab\",\n        \"Immunology core lab QC report received\",\n        \"Immunology core lab QC report received\"\n      ],\n      \"notes\": \"Week 22: Immunogenicity assessments on schedule. 125 subjects enrolled across dose groups. Reactogenicity profiles consistent with prior weeks.\"\n    },\n    {\n      \"index\": 23,\n      \"date\": \"2024-08-05\",\n      \"theme\": \"vaccine_immunogenicity\",\n      \"enrollment\": {\n        \"total_enrolled\": 127,\n        \"active\": 119,\n        \"screen_failures_cumulative\": 30,\n        \"withdrawals_cumulative\": 8,\n        \"by_dose_group\": {\n          \"low_dose\": 29,\n          \"mid_dose\": 32,\n          \"high_dose\": 32,\n          \"placebo\": 34\n        }\n      },\n      \"immunogenicity_by_group\": {\n        \"low_dose\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 62.1,\n            \"sd\": 6.0\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 18.8,\n            \"sd\": 4.0\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 99.1,\n            \"sd\": 10.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 143.0,\n            \"sd\": 15.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 106.0,\n            \"sd\": 11.0\n          },\n          \"seroconversion_pct\": 22.2\n        },\n        \"mid_dose\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 90.7,\n            \"sd\": 9.6\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 29.3,\n            \"sd\": 6.4\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 152.4,\n            \"sd\": 16.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 223.0,\n            \"sd\": 24.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 166.0,\n            \"sd\": 18.0\n          },\n          \"seroconversion_pct\": 34.8\n        },\n        \"high_dose\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 124.8,\n            \"sd\": 13.2\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 40.0,\n            \"sd\": 8.8\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 196.6,\n            \"sd\": 22.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 316.0,\n            \"sd\": 33.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 215.0,\n            \"sd\": 24.0\n          },\n          \"seroconversion_pct\": 49.5\n        },\n        \"placebo\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 15.7,\n            \"sd\": 1.2\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 1.3,\n            \"sd\": 0.8\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 26.5,\n            \"sd\": 2.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 27.0,\n            \"sd\": 3.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 18.0,\n            \"sd\": 2.0\n          },\n          \"seroconversion_pct\": 1.5\n        }\n      },\n      \"injection_site_reactions\": {\n        \"pain_pct\": 48.5,\n        \"erythema_pct\": 28.2,\n        \"swelling_pct\": 15.2,\n        \"induration_pct\": 8.5,\n        \"mean_pain_duration_hours\": 16.6\n      },\n      \"systemic_reactogenicity\": {\n        \"fever_pct\": 12.7,\n        \"fatigue_pct\": 37.2,\n        \"myalgia_pct\": 19.9,\n        \"headache_pct\": 26.9,\n        \"chills_pct\": 10.4\n      },\n      \"safety_labs\": {\n        \"wbc_k\": {\n          \"mean\": 5.9,\n          \"sd\": 1.3\n        },\n        \"lymphocyte_pct\": {\n          \"mean\": 35.8,\n          \"sd\": 6.1\n        },\n        \"neutrophil_pct\": {\n          \"mean\": 53.8,\n          \"sd\": 6.6\n        },\n        \"platelets_k\": {\n          \"mean\": 252,\n          \"sd\": 38\n        },\n        \"crp_mg_l\": {\n          \"mean\": 7.2,\n          \"sd\": 1.3\n        },\n        \"hemoglobin_g_dl\": {\n          \"mean\": 13.8,\n          \"sd\": 1.1\n        }\n      },\n      \"adverse_events\": [\n        {\n          \"ae_id\": \"VI-AE-2361\",\n          \"description\": \"chills\",\n          \"grade\": 2,\n          \"relatedness\": \"possibly related\",\n          \"resolved\": true,\n          \"dose_group\": \"mid_dose\"\n        },\n        {\n          \"ae_id\": \"VI-AE-2378\",\n          \"description\": \"arthralgia\",\n          \"grade\": 1,\n          \"relatedness\": \"possibly related\",\n          \"resolved\": true,\n          \"dose_group\": \"low_dose\"\n        },\n        {\n          \"ae_id\": \"VI-AE-2331\",\n          \"description\": \"lymphadenopathy\",\n          \"grade\": 2,\n          \"relatedness\": \"related\",\n          \"resolved\": true,\n          \"dose_group\": \"low_dose\"\n        }\n      ],\n      \"events\": [\n        \"DSMB safety review teleconference completed\",\n        \"Site 03 monitoring visit, 1 minor findings\",\n        \"Serum sample aliquoting completed for 20 subjects\"\n      ],\n      \"notes\": \"Week 23: Immunogenicity assessments on schedule. 127 subjects enrolled across dose groups. Reactogenicity profiles consistent with prior weeks.\"\n    },\n    {\n      \"index\": 24,\n      \"date\": \"2024-08-12\",\n      \"theme\": \"vaccine_immunogenicity\",\n      \"enrollment\": {\n        \"total_enrolled\": 124,\n        \"active\": 116,\n        \"screen_failures_cumulative\": 34,\n        \"withdrawals_cumulative\": 8,\n        \"by_dose_group\": {\n          \"low_dose\": 31,\n          \"mid_dose\": 30,\n          \"high_dose\": 31,\n          \"placebo\": 32\n        }\n      },\n      \"immunogenicity_by_group\": {\n        \"low_dose\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 57.2,\n            \"sd\": 6.0\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 19.7,\n            \"sd\": 4.0\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 86.3,\n            \"sd\": 10.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 131.0,\n            \"sd\": 15.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 99.0,\n            \"sd\": 11.0\n          },\n          \"seroconversion_pct\": 24.5\n        },\n        \"mid_dose\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 92.9,\n            \"sd\": 9.6\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 31.8,\n            \"sd\": 6.4\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 146.1,\n            \"sd\": 16.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 217.0,\n            \"sd\": 24.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 153.0,\n            \"sd\": 18.0\n          },\n          \"seroconversion_pct\": 37.7\n        },\n        \"high_dose\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 123.9,\n            \"sd\": 13.2\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 43.1,\n            \"sd\": 8.8\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 194.1,\n            \"sd\": 22.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 292.0,\n            \"sd\": 33.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 214.0,\n            \"sd\": 24.0\n          },\n          \"seroconversion_pct\": 44.4\n        },\n        \"placebo\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 11.2,\n            \"sd\": 1.2\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 1.3,\n            \"sd\": 0.8\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 15.1,\n            \"sd\": 2.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 34.0,\n            \"sd\": 3.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 24.0,\n            \"sd\": 2.0\n          },\n          \"seroconversion_pct\": 5.4\n        }\n      },\n      \"injection_site_reactions\": {\n        \"pain_pct\": 45.5,\n        \"erythema_pct\": 14.6,\n        \"swelling_pct\": 17.8,\n        \"induration_pct\": 3.5,\n        \"mean_pain_duration_hours\": 16.0\n      },\n      \"systemic_reactogenicity\": {\n        \"fever_pct\": 21.8,\n        \"fatigue_pct\": 28.7,\n        \"myalgia_pct\": 27.9,\n        \"headache_pct\": 24.7,\n        \"chills_pct\": 14.0\n      },\n      \"safety_labs\": {\n        \"wbc_k\": {\n          \"mean\": 8.1,\n          \"sd\": 1.6\n        },\n        \"lymphocyte_pct\": {\n          \"mean\": 35.2,\n          \"sd\": 7.3\n        },\n        \"neutrophil_pct\": {\n          \"mean\": 57.8,\n          \"sd\": 9.9\n        },\n        \"platelets_k\": {\n          \"mean\": 227,\n          \"sd\": 40\n        },\n        \"crp_mg_l\": {\n          \"mean\": 4.4,\n          \"sd\": 1.5\n        },\n        \"hemoglobin_g_dl\": {\n          \"mean\": 14.0,\n          \"sd\": 1.4\n        }\n      },\n      \"adverse_events\": [\n        {\n          \"ae_id\": \"VI-AE-2478\",\n          \"description\": \"myalgia\",\n          \"grade\": 1,\n          \"relatedness\": \"related\",\n          \"resolved\": true,\n          \"dose_group\": \"low_dose\"\n        },\n        {\n          \"ae_id\": \"VI-AE-2443\",\n          \"description\": \"fatigue\",\n          \"grade\": 1,\n          \"relatedness\": \"possibly related\",\n          \"resolved\": true,\n          \"dose_group\": \"high_dose\"\n        },\n        {\n          \"ae_id\": \"VI-AE-2424\",\n          \"description\": \"fatigue\",\n          \"grade\": 1,\n          \"relatedness\": \"possibly related\",\n          \"resolved\": true,\n          \"dose_group\": \"high_dose\"\n        },\n        {\n          \"ae_id\": \"VI-AE-2476\",\n          \"description\": \"myalgia\",\n          \"grade\": 1,\n          \"relatedness\": \"possibly related\",\n          \"resolved\": true,\n          \"dose_group\": \"high_dose\"\n        }\n      ],\n      \"events\": [\n        \"Site 01 monitoring visit, 0 minor findings\",\n        \"Cold chain temperature log reviewed: all within -70C +/- 5C\",\n        \"Vaccine lot VX-153 temperature excursion assessed: within acceptable range\"\n      ],\n      \"notes\": \"Week 24: Immunogenicity assessments on schedule. 124 subjects enrolled across dose groups. Reactogenicity profiles consistent with prior weeks.\"\n    },\n    {\n      \"index\": 25,\n      \"date\": \"2024-08-19\",\n      \"theme\": \"vaccine_immunogenicity\",\n      \"enrollment\": {\n        \"total_enrolled\": 126,\n        \"active\": 115,\n        \"screen_failures_cumulative\": 43,\n        \"withdrawals_cumulative\": 11,\n        \"by_dose_group\": {\n          \"low_dose\": 30,\n          \"mid_dose\": 31,\n          \"high_dose\": 32,\n          \"placebo\": 33\n        }\n      },\n      \"immunogenicity_by_group\": {\n        \"low_dose\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 58.2,\n            \"sd\": 6.0\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 17.0,\n            \"sd\": 4.0\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 92.2,\n            \"sd\": 10.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 139.0,\n            \"sd\": 15.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 90.0,\n            \"sd\": 11.0\n          },\n          \"seroconversion_pct\": 17.8\n        },\n        \"mid_dose\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 90.9,\n            \"sd\": 9.6\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 31.4,\n            \"sd\": 6.4\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 135.4,\n            \"sd\": 16.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 211.0,\n            \"sd\": 24.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 145.0,\n            \"sd\": 18.0\n          },\n          \"seroconversion_pct\": 36.9\n        },\n        \"high_dose\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 118.7,\n            \"sd\": 13.2\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 41.4,\n            \"sd\": 8.8\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 193.2,\n            \"sd\": 22.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 278.0,\n            \"sd\": 33.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 201.0,\n            \"sd\": 24.0\n          },\n          \"seroconversion_pct\": 46.8\n        },\n        \"placebo\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 14.4,\n            \"sd\": 1.2\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 3.1,\n            \"sd\": 0.8\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 16.7,\n            \"sd\": 2.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 32.0,\n            \"sd\": 3.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 26.0,\n            \"sd\": 2.0\n          },\n          \"seroconversion_pct\": 3.8\n        }\n      },\n      \"injection_site_reactions\": {\n        \"pain_pct\": 40.6,\n        \"erythema_pct\": 23.2,\n        \"swelling_pct\": 7.1,\n        \"induration_pct\": 7.5,\n        \"mean_pain_duration_hours\": 45.0\n      },\n      \"systemic_reactogenicity\": {\n        \"fever_pct\": 8.6,\n        \"fatigue_pct\": 21.6,\n        \"myalgia_pct\": 28.2,\n        \"headache_pct\": 24.5,\n        \"chills_pct\": 8.9\n      },\n      \"safety_labs\": {\n        \"wbc_k\": {\n          \"mean\": 6.4,\n          \"sd\": 2.0\n        },\n        \"lymphocyte_pct\": {\n          \"mean\": 35.6,\n          \"sd\": 8.0\n        },\n        \"neutrophil_pct\": {\n          \"mean\": 52.9,\n          \"sd\": 6.1\n        },\n        \"platelets_k\": {\n          \"mean\": 250,\n          \"sd\": 38\n        },\n        \"crp_mg_l\": {\n          \"mean\": 3.7,\n          \"sd\": 1.5\n        },\n        \"hemoglobin_g_dl\": {\n          \"mean\": 14.8,\n          \"sd\": 1.3\n        }\n      },\n      \"adverse_events\": [\n        {\n          \"ae_id\": \"VI-AE-2506\",\n          \"description\": \"nausea\",\n          \"grade\": 1,\n          \"relatedness\": \"related\",\n          \"resolved\": true,\n          \"dose_group\": \"mid_dose\"\n        },\n        {\n          \"ae_id\": \"VI-AE-2547\",\n          \"description\": \"nausea\",\n          \"grade\": 1,\n          \"relatedness\": \"possibly related\",\n          \"resolved\": true,\n          \"dose_group\": \"high_dose\"\n        }\n      ],\n      \"events\": [\n        \"Cold chain temperature log reviewed: all within -70C +/- 5C\",\n        \"Site 05 monitoring visit, 2 minor findings\",\n        \"Immunology core lab QC report received\"\n      ],\n      \"notes\": \"Week 25: Immunogenicity assessments on schedule. 126 subjects enrolled across dose groups. Reactogenicity profiles consistent with prior weeks.\"\n    },\n    {\n      \"index\": 26,\n      \"date\": \"2024-08-26\",\n      \"theme\": \"vaccine_immunogenicity\",\n      \"enrollment\": {\n        \"total_enrolled\": 126,\n        \"active\": 116,\n        \"screen_failures_cumulative\": 34,\n        \"withdrawals_cumulative\": 10,\n        \"by_dose_group\": {\n          \"low_dose\": 31,\n          \"mid_dose\": 31,\n          \"high_dose\": 31,\n          \"placebo\": 33\n        }\n      },\n      \"immunogenicity_by_group\": {\n        \"low_dose\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 54.7,\n            \"sd\": 6.0\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 18.6,\n            \"sd\": 4.0\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 86.4,\n            \"sd\": 10.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 126.0,\n            \"sd\": 15.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 83.0,\n            \"sd\": 11.0\n          },\n          \"seroconversion_pct\": 24.3\n        },\n        \"mid_dose\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 81.4,\n            \"sd\": 9.6\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 27.3,\n            \"sd\": 6.4\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 132.5,\n            \"sd\": 16.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 195.0,\n            \"sd\": 24.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 145.0,\n            \"sd\": 18.0\n          },\n          \"seroconversion_pct\": 34.2\n        },\n        \"high_dose\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 116.7,\n            \"sd\": 13.2\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 38.7,\n            \"sd\": 8.8\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 188.6,\n            \"sd\": 22.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 270.0,\n            \"sd\": 33.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 196.0,\n            \"sd\": 24.0\n          },\n          \"seroconversion_pct\": 42.1\n        },\n        \"placebo\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 10.8,\n            \"sd\": 1.2\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 5.6,\n            \"sd\": 0.8\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 16.1,\n            \"sd\": 2.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 25.0,\n            \"sd\": 3.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 15.0,\n            \"sd\": 2.0\n          },\n          \"seroconversion_pct\": 0.8\n        }\n      },\n      \"injection_site_reactions\": {\n        \"pain_pct\": 37.3,\n        \"erythema_pct\": 26.0,\n        \"swelling_pct\": 15.8,\n        \"induration_pct\": 4.5,\n        \"mean_pain_duration_hours\": 32.5\n      },\n      \"systemic_reactogenicity\": {\n        \"fever_pct\": 24.8,\n        \"fatigue_pct\": 26.8,\n        \"myalgia_pct\": 32.6,\n        \"headache_pct\": 28.7,\n        \"chills_pct\": 12.0\n      },\n      \"safety_labs\": {\n        \"wbc_k\": {\n          \"mean\": 7.3,\n          \"sd\": 1.6\n        },\n        \"lymphocyte_pct\": {\n          \"mean\": 27.3,\n          \"sd\": 7.7\n        },\n        \"neutrophil_pct\": {\n          \"mean\": 52.7,\n          \"sd\": 6.4\n        },\n        \"platelets_k\": {\n          \"mean\": 252,\n          \"sd\": 43\n        },\n        \"crp_mg_l\": {\n          \"mean\": 4.1,\n          \"sd\": 1.9\n        },\n        \"hemoglobin_g_dl\": {\n          \"mean\": 14.0,\n          \"sd\": 1.2\n        }\n      },\n      \"adverse_events\": [\n        {\n          \"ae_id\": \"VI-AE-2612\",\n          \"description\": \"headache\",\n          \"grade\": 1,\n          \"relatedness\": \"possibly related\",\n          \"resolved\": true,\n          \"dose_group\": \"mid_dose\"\n        },\n        {\n          \"ae_id\": \"VI-AE-2638\",\n          \"description\": \"malaise\",\n          \"grade\": 2,\n          \"relatedness\": \"possibly related\",\n          \"resolved\": true,\n          \"dose_group\": \"high_dose\"\n        }\n      ],\n      \"events\": [\n        \"Reactogenicity diary card collection rate: 93%\",\n        \"Cold chain temperature log reviewed: all within -70C +/- 5C\"\n      ],\n      \"notes\": \"Week 26: Immunogenicity assessments on schedule. 126 subjects enrolled across dose groups. Reactogenicity profiles consistent with prior weeks.\"\n    },\n    {\n      \"index\": 27,\n      \"date\": \"2024-09-02\",\n      \"theme\": \"vaccine_immunogenicity\",\n      \"enrollment\": {\n        \"total_enrolled\": 126,\n        \"active\": 118,\n        \"screen_failures_cumulative\": 42,\n        \"withdrawals_cumulative\": 8,\n        \"by_dose_group\": {\n          \"low_dose\": 30,\n          \"mid_dose\": 31,\n          \"high_dose\": 31,\n          \"placebo\": 34\n        }\n      },\n      \"immunogenicity_by_group\": {\n        \"low_dose\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 49.5,\n            \"sd\": 6.0\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 19.4,\n            \"sd\": 4.0\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 82.5,\n            \"sd\": 10.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 130.0,\n            \"sd\": 15.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 85.0,\n            \"sd\": 11.0\n          },\n          \"seroconversion_pct\": 22.0\n        },\n        \"mid_dose\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 84.9,\n            \"sd\": 9.6\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 30.8,\n            \"sd\": 6.4\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 124.1,\n            \"sd\": 16.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 182.0,\n            \"sd\": 24.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 137.0,\n            \"sd\": 18.0\n          },\n          \"seroconversion_pct\": 32.9\n        },\n        \"high_dose\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 106.8,\n            \"sd\": 13.2\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 40.4,\n            \"sd\": 8.8\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 168.7,\n            \"sd\": 22.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 271.0,\n            \"sd\": 33.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 181.0,\n            \"sd\": 24.0\n          },\n          \"seroconversion_pct\": 44.2\n        },\n        \"placebo\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 14.2,\n            \"sd\": 1.2\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 5.7,\n            \"sd\": 0.8\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 14.3,\n            \"sd\": 2.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 23.0,\n            \"sd\": 3.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 24.0,\n            \"sd\": 2.0\n          },\n          \"seroconversion_pct\": 1.3\n        }\n      },\n      \"injection_site_reactions\": {\n        \"pain_pct\": 38.5,\n        \"erythema_pct\": 22.4,\n        \"swelling_pct\": 13.6,\n        \"induration_pct\": 3.1,\n        \"mean_pain_duration_hours\": 29.0\n      },\n      \"systemic_reactogenicity\": {\n        \"fever_pct\": 12.8,\n        \"fatigue_pct\": 40.2,\n        \"myalgia_pct\": 20.0,\n        \"headache_pct\": 24.6,\n        \"chills_pct\": 11.6\n      },\n      \"safety_labs\": {\n        \"wbc_k\": {\n          \"mean\": 7.1,\n          \"sd\": 1.9\n        },\n        \"lymphocyte_pct\": {\n          \"mean\": 33.7,\n          \"sd\": 6.8\n        },\n        \"neutrophil_pct\": {\n          \"mean\": 51.7,\n          \"sd\": 9.7\n        },\n        \"platelets_k\": {\n          \"mean\": 226,\n          \"sd\": 43\n        },\n        \"crp_mg_l\": {\n          \"mean\": 1.8,\n          \"sd\": 1.4\n        },\n        \"hemoglobin_g_dl\": {\n          \"mean\": 13.9,\n          \"sd\": 1.0\n        }\n      },\n      \"adverse_events\": [\n        {\n          \"ae_id\": \"VI-AE-2770\",\n          \"description\": \"fatigue\",\n          \"grade\": 1,\n          \"relatedness\": \"possibly related\",\n          \"resolved\": true,\n          \"dose_group\": \"mid_dose\"\n        },\n        {\n          \"ae_id\": \"VI-AE-2712\",\n          \"description\": \"arthralgia\",\n          \"grade\": 2,\n          \"relatedness\": \"related\",\n          \"resolved\": true,\n          \"dose_group\": \"low_dose\"\n        },\n        {\n          \"ae_id\": \"VI-AE-2707\",\n          \"description\": \"myalgia\",\n          \"grade\": 1,\n          \"relatedness\": \"possibly related\",\n          \"resolved\": true,\n          \"dose_group\": \"high_dose\"\n        },\n        {\n          \"ae_id\": \"VI-AE-2768\",\n          \"description\": \"arthralgia\",\n          \"grade\": 1,\n          \"relatedness\": \"possibly related\",\n          \"resolved\": true,\n          \"dose_group\": \"high_dose\"\n        },\n        {\n          \"ae_id\": \"VI-AE-2721\",\n          \"description\": \"lymphadenopathy\",\n          \"grade\": 1,\n          \"relatedness\": \"possibly related\",\n          \"resolved\": true,\n          \"dose_group\": \"high_dose\"\n        }\n      ],\n      \"events\": [\n        \"Vaccine lot VX-944 temperature excursion assessed: within acceptable range\",\n        \"Site 01 monitoring visit, 0 minor findings\"\n      ],\n      \"notes\": \"Week 27: Immunogenicity assessments on schedule. 126 subjects enrolled across dose groups. Reactogenicity profiles consistent with prior weeks.\"\n    },\n    {\n      \"index\": 28,\n      \"date\": \"2024-09-09\",\n      \"theme\": \"vaccine_immunogenicity\",\n      \"enrollment\": {\n        \"total_enrolled\": 127,\n        \"active\": 116,\n        \"screen_failures_cumulative\": 50,\n        \"withdrawals_cumulative\": 11,\n        \"by_dose_group\": {\n          \"low_dose\": 31,\n          \"mid_dose\": 30,\n          \"high_dose\": 32,\n          \"placebo\": 34\n        }\n      },\n      \"immunogenicity_by_group\": {\n        \"low_dose\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 43.8,\n            \"sd\": 6.0\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 21.0,\n            \"sd\": 4.0\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 77.7,\n            \"sd\": 10.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 108.0,\n            \"sd\": 15.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 89.0,\n            \"sd\": 11.0\n          },\n          \"seroconversion_pct\": 16.0\n        },\n        \"mid_dose\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 79.8,\n            \"sd\": 9.6\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 29.3,\n            \"sd\": 6.4\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 120.1,\n            \"sd\": 16.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 188.0,\n            \"sd\": 24.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 138.0,\n            \"sd\": 18.0\n          },\n          \"seroconversion_pct\": 31.7\n        },\n        \"high_dose\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 103.7,\n            \"sd\": 13.2\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 40.4,\n            \"sd\": 8.8\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 165.8,\n            \"sd\": 22.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 261.0,\n            \"sd\": 33.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 173.0,\n            \"sd\": 24.0\n          },\n          \"seroconversion_pct\": 46.3\n        },\n        \"placebo\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 12.7,\n            \"sd\": 1.2\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 4.8,\n            \"sd\": 0.8\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 20.3,\n            \"sd\": 2.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 28.0,\n            \"sd\": 3.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 10.0,\n            \"sd\": 2.0\n          },\n          \"seroconversion_pct\": 0.8\n        }\n      },\n      \"injection_site_reactions\": {\n        \"pain_pct\": 42.3,\n        \"erythema_pct\": 27.5,\n        \"swelling_pct\": 6.6,\n        \"induration_pct\": 11.3,\n        \"mean_pain_duration_hours\": 26.1\n      },\n      \"systemic_reactogenicity\": {\n        \"fever_pct\": 10.6,\n        \"fatigue_pct\": 36.8,\n        \"myalgia_pct\": 31.4,\n        \"headache_pct\": 20.1,\n        \"chills_pct\": 13.7\n      },\n      \"safety_labs\": {\n        \"wbc_k\": {\n          \"mean\": 8.1,\n          \"sd\": 1.3\n        },\n        \"lymphocyte_pct\": {\n          \"mean\": 33.4,\n          \"sd\": 7.5\n        },\n        \"neutrophil_pct\": {\n          \"mean\": 61.2,\n          \"sd\": 7.8\n        },\n        \"platelets_k\": {\n          \"mean\": 230,\n          \"sd\": 41\n        },\n        \"crp_mg_l\": {\n          \"mean\": 1.8,\n          \"sd\": 1.6\n        },\n        \"hemoglobin_g_dl\": {\n          \"mean\": 14.0,\n          \"sd\": 0.8\n        }\n      },\n      \"adverse_events\": [\n        {\n          \"ae_id\": \"VI-AE-2852\",\n          \"description\": \"fever\",\n          \"grade\": 2,\n          \"relatedness\": \"related\",\n          \"resolved\": true,\n          \"dose_group\": \"mid_dose\"\n        },\n        {\n          \"ae_id\": \"VI-AE-2869\",\n          \"description\": \"malaise\",\n          \"grade\": 2,\n          \"relatedness\": \"possibly related\",\n          \"resolved\": true,\n          \"dose_group\": \"high_dose\"\n        },\n        {\n          \"ae_id\": \"VI-AE-2810\",\n          \"description\": \"fatigue\",\n          \"grade\": 2,\n          \"relatedness\": \"related\",\n          \"resolved\": true,\n          \"dose_group\": \"mid_dose\"\n        },\n        {\n          \"ae_id\": \"VI-AE-2891\",\n          \"description\": \"arthralgia\",\n          \"grade\": 1,\n          \"relatedness\": \"possibly related\",\n          \"resolved\": true,\n          \"dose_group\": \"mid_dose\"\n        },\n        {\n          \"ae_id\": \"VI-AE-2868\",\n          \"description\": \"arthralgia\",\n          \"grade\": 2,\n          \"relatedness\": \"possibly related\",\n          \"resolved\": true,\n          \"dose_group\": \"low_dose\"\n        }\n      ],\n      \"events\": [\n        \"Cold chain temperature log reviewed: all within -70C +/- 5C\",\n        \"Vaccination day 1: 25 subjects received scheduled dose\",\n        \"Cold chain temperature log reviewed: all within -70C +/- 5C\"\n      ],\n      \"notes\": \"Week 28: Immunogenicity assessments on schedule. 127 subjects enrolled across dose groups. Reactogenicity profiles consistent with prior weeks.\"\n    },\n    {\n      \"index\": 29,\n      \"date\": \"2024-09-16\",\n      \"theme\": \"vaccine_immunogenicity\",\n      \"enrollment\": {\n        \"total_enrolled\": 126,\n        \"active\": 112,\n        \"screen_failures_cumulative\": 50,\n        \"withdrawals_cumulative\": 14,\n        \"by_dose_group\": {\n          \"low_dose\": 29,\n          \"mid_dose\": 32,\n          \"high_dose\": 33,\n          \"placebo\": 32\n        }\n      },\n      \"immunogenicity_by_group\": {\n        \"low_dose\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 48.2,\n            \"sd\": 6.0\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 21.4,\n            \"sd\": 4.0\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 68.8,\n            \"sd\": 10.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 101.0,\n            \"sd\": 15.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 71.0,\n            \"sd\": 11.0\n          },\n          \"seroconversion_pct\": 17.3\n        },\n        \"mid_dose\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 76.7,\n            \"sd\": 9.6\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 27.6,\n            \"sd\": 6.4\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 114.2,\n            \"sd\": 16.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 180.0,\n            \"sd\": 24.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 124.0,\n            \"sd\": 18.0\n          },\n          \"seroconversion_pct\": 33.8\n        },\n        \"high_dose\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 102.4,\n            \"sd\": 13.2\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 43.7,\n            \"sd\": 8.8\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 163.8,\n            \"sd\": 22.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 235.0,\n            \"sd\": 33.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 178.0,\n            \"sd\": 24.0\n          },\n          \"seroconversion_pct\": 36.0\n        },\n        \"placebo\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 7.7,\n            \"sd\": 1.2\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 5.9,\n            \"sd\": 0.8\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 11.5,\n            \"sd\": 2.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 28.0,\n            \"sd\": 3.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 20.0,\n            \"sd\": 2.0\n          },\n          \"seroconversion_pct\": 5.3\n        }\n      },\n      \"injection_site_reactions\": {\n        \"pain_pct\": 58.9,\n        \"erythema_pct\": 23.1,\n        \"swelling_pct\": 16.4,\n        \"induration_pct\": 3.6,\n        \"mean_pain_duration_hours\": 22.2\n      },\n      \"systemic_reactogenicity\": {\n        \"fever_pct\": 6.3,\n        \"fatigue_pct\": 39.6,\n        \"myalgia_pct\": 19.0,\n        \"headache_pct\": 20.2,\n        \"chills_pct\": 10.2\n      },\n      \"safety_labs\": {\n        \"wbc_k\": {\n          \"mean\": 7.1,\n          \"sd\": 1.3\n        },\n        \"lymphocyte_pct\": {\n          \"mean\": 28.9,\n          \"sd\": 6.4\n        },\n        \"neutrophil_pct\": {\n          \"mean\": 53.7,\n          \"sd\": 5.1\n        },\n        \"platelets_k\": {\n          \"mean\": 227,\n          \"sd\": 42\n        },\n        \"crp_mg_l\": {\n          \"mean\": 7.3,\n          \"sd\": 1.5\n        },\n        \"hemoglobin_g_dl\": {\n          \"mean\": 14.3,\n          \"sd\": 0.9\n        }\n      },\n      \"adverse_events\": [\n        {\n          \"ae_id\": \"VI-AE-2903\",\n          \"description\": \"fever\",\n          \"grade\": 2,\n          \"relatedness\": \"possibly related\",\n          \"resolved\": true,\n          \"dose_group\": \"low_dose\"\n        },\n        {\n          \"ae_id\": \"VI-AE-2980\",\n          \"description\": \"malaise\",\n          \"grade\": 1,\n          \"relatedness\": \"possibly related\",\n          \"resolved\": true,\n          \"dose_group\": \"low_dose\"\n        },\n        {\n          \"ae_id\": \"VI-AE-2908\",\n          \"description\": \"nausea\",\n          \"grade\": 1,\n          \"relatedness\": \"possibly related\",\n          \"resolved\": true,\n          \"dose_group\": \"low_dose\"\n        },\n        {\n          \"ae_id\": \"VI-AE-2931\",\n          \"description\": \"chills\",\n          \"grade\": 1,\n          \"relatedness\": \"possibly related\",\n          \"resolved\": true,\n          \"dose_group\": \"high_dose\"\n        },\n        {\n          \"ae_id\": \"VI-AE-2964\",\n          \"description\": \"headache\",\n          \"grade\": 2,\n          \"relatedness\": \"possibly related\",\n          \"resolved\": true,\n          \"dose_group\": \"low_dose\"\n        }\n      ],\n      \"events\": [\n        \"Serology samples shipped to central immunology lab\",\n        \"Site 02 monitoring visit, 3 minor findings\",\n        \"Vaccine lot VX-588 temperature excursion assessed: within acceptable range\"\n      ],\n      \"notes\": \"Week 29: Immunogenicity assessments on schedule. 126 subjects enrolled across dose groups. Reactogenicity profiles consistent with prior weeks.\"\n    },\n    {\n      \"index\": 30,\n      \"date\": \"2024-09-23\",\n      \"theme\": \"vaccine_immunogenicity\",\n      \"enrollment\": {\n        \"total_enrolled\": 126,\n        \"active\": 115,\n        \"screen_failures_cumulative\": 40,\n        \"withdrawals_cumulative\": 11,\n        \"by_dose_group\": {\n          \"low_dose\": 29,\n          \"mid_dose\": 31,\n          \"high_dose\": 33,\n          \"placebo\": 33\n        }\n      },\n      \"immunogenicity_by_group\": {\n        \"low_dose\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 42.4,\n            \"sd\": 6.0\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 16.3,\n            \"sd\": 4.0\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 63.7,\n            \"sd\": 10.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 109.0,\n            \"sd\": 15.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 79.0,\n            \"sd\": 11.0\n          },\n          \"seroconversion_pct\": 12.6\n        },\n        \"mid_dose\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 74.5,\n            \"sd\": 9.6\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 28.3,\n            \"sd\": 6.4\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 119.2,\n            \"sd\": 16.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 177.0,\n            \"sd\": 24.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 117.0,\n            \"sd\": 18.0\n          },\n          \"seroconversion_pct\": 30.5\n        },\n        \"high_dose\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 100.2,\n            \"sd\": 13.2\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 38.5,\n            \"sd\": 8.8\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 157.3,\n            \"sd\": 22.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 228.0,\n            \"sd\": 33.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 167.0,\n            \"sd\": 24.0\n          },\n          \"seroconversion_pct\": 38.4\n        },\n        \"placebo\": {\n          \"igg_titer_gmu\": {\n            \"mean\": 13.5,\n            \"sd\": 1.2\n          },\n          \"igm_titer_gmu\": {\n            \"mean\": 5.8,\n            \"sd\": 0.8\n          },\n          \"neutralizing_ab_id50\": {\n            \"mean\": 13.9,\n            \"sd\": 2.0\n          },\n          \"cd4_response_sfc_per_10e6\": {\n            \"mean\": 23.0,\n            \"sd\": 3.0\n          },\n          \"cd8_response_sfc_per_10e6\": {\n            \"mean\": 16.0,\n            \"sd\": 2.0\n          },\n          \"seroconversion_pct\": 6.1\n        }\n      },\n      \"injection_site_reactions\": {\n        \"pain_pct\": 60.2,\n        \"erythema_pct\": 24.2,\n        \"swelling_pct\": 14.1,\n        \"induration_pct\": 6.4,\n        \"mean_pain_duration_hours\": 33.5\n      },\n      \"systemic_reactogenicity\": {\n        \"fever_pct\": 16.8,\n        \"fatigue_pct\": 37.2,\n        \"myalgia_pct\": 31.9,\n        \"headache_pct\": 18.9,\n        \"chills_pct\": 12.8\n      },\n      \"safety_labs\": {\n        \"wbc_k\": {\n          \"mean\": 5.6,\n          \"sd\": 1.3\n        },\n        \"lymphocyte_pct\": {\n          \"mean\": 27.5,\n          \"sd\": 4.9\n        },\n        \"neutrophil_pct\": {\n          \"mean\": 63.9,\n          \"sd\": 7.0\n        },\n        \"platelets_k\": {\n          \"mean\": 254,\n          \"sd\": 43\n        },\n        \"crp_mg_l\": {\n          \"mean\": 3.4,\n          \"sd\": 1.8\n        },\n        \"hemoglobin_g_dl\": {\n          \"mean\": 14.7,\n          \"sd\": 1.0\n        }\n      },\n      \"adverse_events\": [\n        {\n          \"ae_id\": \"VI-AE-3077\",\n          \"description\": \"arthralgia\",\n          \"grade\": 1,\n          \"relatedness\": \"related\",\n          \"resolved\": true,\n          \"dose_group\": \"mid_dose\"\n        },\n        {\n          \"ae_id\": \"VI-AE-3067\",\n          \"description\": \"injection site pain\",\n          \"grade\": 1,\n          \"relatedness\": \"possibly related\",\n          \"resolved\": true,\n          \"dose_group\": \"mid_dose\"\n        }\n      ],\n      \"events\": [\n        \"DSMB safety review teleconference completed\",\n        \"Serology samples shipped to central immunology lab\"\n      ],\n      \"notes\": \"Week 30: Immunogenicity assessments on schedule. 126 subjects enrolled across dose groups. Reactogenicity profiles consistent with prior weeks.\"\n    }\n  ]\n}",
  "metadata": {
    "theme": "vaccine_immunogenicity",
    "theme_index": 1,
    "episode_count": 30,
    "source": "pre-generated",
    "layer_name": "outline",
    "layer_level": 1,
    "build_fingerprint": {
      "scheme": "synix:build:v1",
      "digest": "f2034ad3bb3a7e5c8863c56a14ab2e64f4322839e5ca9d1e313b91f59e748164",
      "components": {
        "transform": "95b93afff1fd0996ff411e91087777e346ee1d11967fb0b147a9ed652c56d2ca",
        "inputs": "adb73f1617b2cb78"
      }
    },
    "transform_fingerprint": {
      "scheme": "synix:transform:v2",
      "digest": "95b93afff1fd0996ff411e91087777e346ee1d11967fb0b147a9ed652c56d2ca",
      "components": {
        "transform_id": "b34546bdc16464ec",
        "source": "c6a454d687ba7eb1",
        "model": "9bc2ebe12e4c88f9"
      }
    }
  }
}